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INTRODUCTION 
 
      Diabetes mellitus is fast attaining epidemic proportions in India ,with 
nearly 62 million individuals diagnosed with the disease. Apart from the 
macrovascular complications they are at risk of developing microvascular 
complications like retinopathy, nephropathy and neuropathy associated with 
high morbidity Increased platelet reactivity and insulin resistance are considered 
to be the prime determinants of all the vascular complications in diabetes . 
Recent studies point to the role of mean platelet volume to be an important 
marker for thromboembolism. 
 
 
AIMS AND OBJECTIVES 
 
 To determine the association between mean platelet volume and type 2 
diabetes mellitus 
 
 To compare the values of Mean Platelet Volume in type 2 diabetic 
subjects on insulin therapy and those on oral hypoglycaemic agents. 
 
 To determine the association of microvascular complications with mean 
platelet volume. 
 
 
MATERIALS AND METHODS 
 
After obtaining an informed consent from the patients a detailed clinical 
history will be obtained including the duration since diagnosis of DM and 
commencement of treatment, followed by a  physical examination including 
fundus examination.Then lab investigations like fasting blood glucose, 
2 hr postprandial blood glucose,Hb A1C, complete haemogram, mean platelet 
volume will be performed and results will be correlated 
 
RESULTS 
 
Among the 50 subjects selected for the study, 19 were on insulin therapy 
and 31 were on oral hypoglycaemic agents.the MPV was found to have a 
positive correlation between fasting blood glucose , postprandial blood glucose , 
HbA1C , and presence of retinopathy. The mean platelet volume was 
significantly lower in the group on insulin therapy than those taking OHAs, and 
this observation was statistically significant.( p value =0.000) 
 
CONCLUSION  
 
 The Mean platelet volume was found to be lower in the insulin therapy 
group indicating that the early initiation of insulin  therapy  in the diabetic 
population not only controls blood sugar but also lowers the MPV and protects 
from the vascular complications. There was a definite positive correlation 
between microvascular complications and MPV indicating a increased platelet 
reactivity  among these individuals. Thus MPV can serve as a cost effective tool 
in monitoring the platelet reactivity and monitoring vascular complications of 
diabetes. 
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                   INTRODUCTION   
                         Diabetes mellitus is fast attaining epidemic proportions in India 
,with nearly 62 million individuals diagnosed with the disease.
(1)
India became 
the forerunner of the global diabetic population in the year 2000 with 31.7 
million  diabetic people , closely followed by China with 20.8 million and 
United states with 17.7 million.
(1)
Recent estimates published by Wild et al 
predicted a doubling of the global diabetic population from 171 million in 2000 
to 366 million in 2030 with a highest increase  in our nation.
(1) 
                 The macrovascular complications of diabetes include cardiovascular, 
cerebrovascular and peripheral arterial disease. Hyperglycemia as such or 
diabetes mellitus or both is said to account for nearly 3 million deaths due to 
coronary events every year. 60 % of the deaths in diabetic people is due to 
cardiovascular diseases. Adverse coronary events occur at a much younger age 
in diabetic individuals and the incidence is almost the same in both men and 
women. 
            Among the 239 diabetic patients followed in the  Framingham Heart 
Study of 1948 , there was a three fold increase in cardiovascular mortality, 
leading to diabetes being considered a  risk equivalent of 
CAD(3)
. In the GUSTO-
1 trial the analysis of  patients with ST elevation MI showed an increase in 30 
day mortality in the diabetic population compared to non diabetics.  . 
Similarly the odds of a diabetic person developing ischaemic stroke was 2-3 
times higher than the non diabetic individual.
(4-7) 
                 Apart from the macrovascular complications they are at risk of 
developing microvascular complications like retinopathy, nephropathy and 
neuropathy associated with high morbidity
(8)
. Numerous mechanisms could be 
sought to explain this increased risk, however the most important among all 
would be the presence of a pro inflammatory and pro thrombotic state. And the 
prominent role played by platelets cannot be undermined. Increased platelet 
reactivity and insulin resistance are considered to be the prime determinants of 
all the vascular complications in diabetes. This is re iterated by the outcome of 
the TRITON –TIMI 38 study which showed a significant decrease in ischaemic 
events with aggressive antiplatelet therapy in the diabetic population in 
comparison to anti diabetic people. 
                            Platelets have a vital role to play in maintaining hemostasis. 
The measurement of platelet size and volume are considered as important 
determinants of platelet function. Recent studies point to the role of mean 
platelet volume to be an important marker for thromboembolism
(9)
, MI and 
ischaemic stroke. Platelets when larger in size are considered to be more 
reactive with increased pro-thrombotic factor thromboxane A2 release and 
hence a increased thrombogenic potential
(10)
 . The mean platelet volume was 
found to be higher in diabetic population than the non diabetics and it was found  
  
to improve with good glycemic control(11). MPV is also considered to 
influence the development of micro and macro vascular complications of 
diabetes mellitus which has been dealt in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES 
 
 To determine the association between mean platelet volume and type 2 
diabetes mellitus 
 
 To compare the values of Mean Platelet Volume in type 2 diabetic 
subjects on insulin therapy and those on oral hypoglycaemic agents. 
 
 To determine the association of microvascular complications with mean 
platelet volume. 
 
  
  
 
 
 
 
 
 
                         
 
 
                          LITERATURE REVIEW  
                           DIABETES MELLITUS AN OVERVIEW 
                            
                          Diabetes mellitus is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat, and protein metabolism resulting from defects 
in insulin secretion, insulin action, or both. 
THE INDIAN SCENARIO 
                Diabetes mellitus in India is a constantly rising problem. Recent 
studies indicate that by 2030 there will be up to 79.4 million individuals 
suffering from diabetes mellitus   in India.
(1) 
               The morbidity and mortality produced by diabetes and its   
complications are  so varied and widespread that they will be a substantial 
burden on the family as well as the society. The fact that there is increasingly 
numerous data supporting the occurrence of   complications at much younger 
ages in India.  The current trend of migration of the population from the rural to 
the urban areas, changes in life style favouring sedentary habits and the 
economic  boom have all paved to the increased incidence of diabetes in our 
country. Inspite of this rapid expansion in the diabetic population there remains 
a definite void in  relation to the studies on DM , bringing out the cultural, socio 
economic ,geographical influence on the disease.  
                 
Figure 1 PREVALANCE OF DIABETES 2013,IDF 
                    
 
                         Diabetes in Indians is found to occur at a relatively lower body 
mass index compared to the European or other counterparts.
(12,13)
  thus Indians 
who are non-obese  and with a lower BMI are at equal risk of  developing 
diabetes.  Also Indians are  predisposed genetically to develop  coronary artery 
disease  as a result of increased incidence of  dyslipidaemia and low HDL. All 
these factors make us Indians more susceptible for the development of diabetic 
complications at a much lower age (20-40 years)  in comparison with the 
Caucasians (>50 years).
(14)
 Thus the initiation of early screening programs to 
detect individuals with pre diabetes in high risk population like children and 
adults with BMI ≥25 and pregnant women, can pave way to regulate and yield 
positive health outcomes . 
 
The presence chronic state of hyperglycemia in diabetes leads to prolonged 
damage, impaired function, and failure of various  organ systems, mainly the 
kidneys, eyes, kidneys, the nervous system , the  heart, and blood vessels. 
                  Various mechanisms are attributed to the development of diabetes. 
Some of them being an autoimmune destruction of the beta-cells of the islet of   
pancreas with resultant deficiency of insulin and abnormal metabolism leading 
to resistance to the action of insulin. The common factor leading to defects in 
the metabolism of carbohydrate, fat, and proteins is the defective action on 
target tissues produced by a deficiency   of insulin.  
                  The classical triad of symptoms associated with hyperglycemia 
includes polyuria, polydipsia, weight loss, and on occasions associated with 
polyphagia, and blurring of vision along with an increased susceptibility to 
infections.  The acute often life-threatening complications of hyperglycemia  
and diabetes are  ketoacidosis or  Non -ketotic hyperosmolar  coma. The long-
term complications of diabetes include retinopathy, nephropathy and 
neuropathy. With the risk of   developing potential loss of  vision , chronic renal 
 failure; occurrence of  ulcers in foot , rarely amputations, and Charcot joints; 
also the resulting autonomic neuropathy can lead to GI, cardiovascular 
,genitourinary and sexual dysfunction. The macrovascular complications are 
more common in diabetes and they are highly prone to atherosclerotic 
cardiovascular, cerebrovascular and peripheral arterial, diseases.   
CLASSIFICATION 
                         Diabetes is mainly classified into four major categories as   
 Type 1 diabetes mellitus 
 Type 2 diabetes mellitus 
 Other specific types 
 Gestational diabetes mellitus  
 
Figure 2 natural history of DM 
  
 
Type 1 diabetes 
                               Its   associated with the destruction of beta cells leading to 
absolute deficiency of insulin, often called as the immune mediated diabetes. 
Only 5–10% of the overall diabetic population fall under this type. Earlier 
referred as insulin dependent diabetes or juvenile-onset diabetes. The presence 
of auto antibodies   against the islet cell , insulin,  GAD (GAD65), and  to the 
tyrosine phosphatases  indicate an immune mediated insult
(15)
. 85–90% of 
patients with type 1DM have one or more of these antibodies. Further, there 
exists a strong HLA associations in this form of diabetes. Early adolescence or 
childhood is the most common age group for the occurrence of this immune 
mediated pathology, however it can occur at any age as well as late as in the 8th 
and 9th decades. There is an increased incidence of autoimmune diseases in 
these subjects. 
  
Idiopathic diabetes.  
                   Some persons with type 1 DM have no specific etiology, but exhibit 
insulin deficiency and there is a clear absence  of any of the auto antibodies ,but 
have no evidence of autoimmunity, and they are denoted as persons with 
idiopathic diabetes for the lack of a clear etiology.
(16) 
 
Type 2 diabetes 
                       The underlying process can be explained by a resistance to 
insulin action with a relative deficiency of insulin or a clear defect in the 
secretion of insulin associated with a IR . 90–95% of diabetics fall under this 
category. It’s also called as non–insulin-dependent diabetes, or adult onset 
diabetes. 
                     A significant proportion of patients with type 2 DM are obese and 
this can contribute to insulin resistance as discussed further in this study. And 
those who are not obese are found to have a higher incidence of visceral 
adiposity. This form can go undiagnosed for a prolonged period as the onset of 
hyperglycemia takes several years and the earlier stages are not usually 
characterised by the typical symptoms. 
 
CATEGORIES OF INCREASED RISK FOR DIABETES 
              
                  The Expert Committee on Diagnosis and Classification of Diabetes 
Mellitus 
(17)
 identified a group of people who did not fit the diagnostic criteria 
for diabetes yet had glucose values higher than what was considered normal. 
And they were classified as having impaired glucose tolerance. They were 
referred to as having pre-diabetes .With an increased tendency to develop 
diabetes in future. Lifestyle  modifications , increase in the physical activity and 
a weight loss of  5–10% , and  Specific drugs have been proven  to prevent or 
delay the development of diabetes in people with IGT. 
 
 
Figure 3 impaired glucose tolerance/pre diabetes 
 
 
 
 
     
Figure 4 diagnosis of dm and pre diabetes 
 
  
 
Criteria for diagnosis of type 2 DM:  
                      
                      This takes into account fasting blood glucose and  a 2 hr plasma 
glucose on OGTT, and HbA1c which is a marker of chronic glycemic status 
over a period of 2- 3 months. 
 
 
 
 
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS 
 
 
 
 
Figure 5 diagnostic criteria for DM 
 
 
 
 
  
 
INSULIN RESISTANCE AND THE PATHOGENESIS OF TYPE 2 
DIABETES 
                        Insulin resistance indicates the to resistance to its various 
metabolic effects , like  the suppression of endogenous glucose production, the 
stimulatory effects  on the peripheral (mainly  skeletal muscle) glucose uptake 
and synthesis of glycogen, and  finally the inhibition of  adipose tissue lipolysis. 
Numerous studies have demonstrated the occurrence of insulin resistance prior 
to the onset of type 2 diabetes by nearly 10 to 20 years. Insulin resistance is 
considered as the best clinical predictor of subsequent development of type 2 
diabetes
(18,19)
.. However, for the occurrence of overt diabetes mellitus there is a 
necessity for an   additional impairment in insulin secretion
(18)
 .When  the  β-cell 
function adequately , individuals continue to  compensate indefinitely for 
insulin resistance by developing hyperinsulinemia . But  however , the risk of  
developing atherosclerosis is found to be similar  in non-diabetic individuals 
with insulin resistance  patients with overt with type 2 diabetes 
(20)
. 
 
 Contributors of tissue specific IR: 
SKELETAL MUSCLE 
                             A universally recognized feature of type 2 diabetes  is  
resistance to insulin occurring in the skeletal muscle , which could be either due  
to genetic factors or metabolic factors. Skeletal muscle is quantitatively the 
most  prominent  organ  involved in the homeostasis of glucose, as  it accounts 
for ~80% of glucose utilization  following glucose ingestion or infusion. Thus, 
the reduced capacity of insulin to stimulate the disposal of glucose by   skeletal 
muscle is of prime importance to whole-body glucose homeostasis. Impairment 
of glucose uptake and  its phosphorylation which are dependent on insulin  have 
been identified  at initial stages of type 2 diabetes
(21)
. The experimental studies 
have showed  skeletal muscle playing a vital role as a site of insulin action, still 
there is indication of presence of alternate pathways leading to glucose uptake 
and  translocation of GLUT4 in skeletal muscle which is found to for the  lack 
of  insulin receptor.                         
                          The transport of 3- O -methylglucose  into the  skeletal muscle 
from patients with type 2 diabetes which is dependent on insulin is found to be  
substantially lower than in normal controls, demonstrating that decreased 
skeletal muscle uptake contributes to impaired peripheral glucose uptake
(22,23)
. A 
uniform finding in both obesity and type 2 diabetes is decreased insulin receptor 
substrate-1 (IRS-1) associated tyrosine phosphorylation and Phosphotidyl 
ionositol 3-kinase activity in skeletal muscle
(24,25)
. In addition to this down 
regulation of proximal insulin signaling, several negative regulators of insulin 
signaling are up regulated in insulin resistance. Plasma-cell differentiation 
factor-1 (PC-1) is a membrane glycoprotein that acts as an intrinsic inhibitor of 
insulin receptor tyrosine kinase activity
(26)
 It has been suggested that increased 
expression of PC-1 in skeletal muscle of obese subjects is more strongly 
associated with down regulation of the insulin receptor tyrosine phosphorylation 
, than with decreased insulin receptor expression
(27)
 .Similarly there is an 
increase in the activity of  membrane bound tyrosine phosphatase especially  
that of  PTP-1B
(28)
, which negatively regulates phosphorylation of insulin 
receptors, leading to impaired peripheral uptake. 
 
ADIPOSE TISSUE 
                          Insulin resistance in adipose tissue is characterized by a 
reduction in the suppression of lipolysis in the adipose tissue leading to an 
elevated level of free fatty acids. This is seen in both obese insulin-resistant 
individuals and patients with type 2 diabetes .The occurrence of the same defect 
in first-degree relatives of patients who have normal glucose tolerance 
(29) 
indicates that abnormal suppression of plasma free fatty acids mediated through 
insulin is  early abnormality in people with a genetic predisposition to IR. The 
reduction or absence of aP2, a fatty acid binding protein found in  adipose tissue 
results in reduction in adipose tissue lipolysis and an elevated mass of  adipose 
tissue
(30)
 .this is accompanied by a paradoxical decrease  in plasma lipids and a 
better insulin sensitivity and better secretion of  insulin 
(31)
. This brings to light  
that increase of adipose tissue mass may have beneficial effects against insulin 
resistance. This strategy of adipose tissue serving a protective function to  other 
tissues from the deleterious effects of excessive FFA  is reiterated by the fact 
that overexpression of GLUT4 in adipose tissue of experimental models 
produces both an  improvement in sensitivity to insulin and increase in  mass of 
adipose tissue.     
 
LIVER 
                    The concept of glucose production by liver is an area of 
controversy, as to if it is regulated by insulin or is being regulated by the extra 
hepatic metabolic effects. The proposed mechanism is that, the production of 
glucose is being suppressed by decreasing the input of free fatty acids and 
amino acids  from  adipose tissues and muscle, this being mediated by insulin is 
found to reduce hepatic gluconeogenesis 
(32)
.  For this process to occur normally 
there has to be an adequate response to insulin at the level of adipose tissues.it is 
this ability of insulin in the periphery to control the  glucose production  that is 
responsible for supressing  circulation of free fatty acids. 
                       The onset of overt diabetes requires the presence of insulin 
resistance at the hepatic level. Studies indicate that  hepatic insulin resistance is 
due to an inherent  abnormality of insulin signaling  occurring at the  
hepatocyte.   
BRAIN 
                      Insulin exerts a central action on the hypothalamus, is is 
responsible for suppression of appetite ( centrally mediated ) and various other 
metabolic effects. Resistance to this action of insulin in the hypothalamus can 
result in centrally mediated insulin resistance. There is a wide distribution of 
insulin receptors in  several areas of  brain
(34)
  which are associated with the 
regulation of satiety 
(34)
.the main pathway of  glucose disposal in most of 
neurons is through an insulin-independent mechanism , however in the 
hypothalamus and other specific areas of the brain, its mediated by the insulin-
responsive glucose transporter GLUT4.  
               This proposed mechanism of central inhibition mediated by insulin 
also greatly suppressed ability of exogenously infused insulin to bring down the 
hepatic glucose output. This clearly points to the vital role played by the insulin 
receptor in the hypothalamus in regulating the of glucose metabolism of liver. 
 GENETIC CAUSES OF INSULIN RESISTANCE 
                    There is a defect in both the action and secretion of insulin in  type 
2 diabetes, and both are considered to be genetically predetermined. 
Furthermore, there is a nearly 100% concordance in diagnosis of type 2 diabetes 
between monozygotic twins but only a 20% concordance between dizygotic 
twins 
(88)
. 
 
 INSULIN RECEPTOR MUTATIONS 
                     There are nearly 100 mutations occuring  naturally  in the insulin 
receptor gene and most of them are associated with resistance to insulin 
action.
(36)
IR also occurs with the complete absence of these receptors 
(37)
. 
Leprechaunism is the most severe form of such mutation in insulin receptor 
syndromes, it’s characterized by IUGR and characteristic dysmorphic facies   
comprising of thick lips, low set ears, prominent eyes, upturned nostrils, and 
thick skin with the absence of subcutaneous fat. The milder form of such 
mutation is the Rabson- syndrome where patients have life expectancies nearly 
15 years. These syndromes being characterised fasting hypoglycaemia and 
prominent  mitogenic features, inspite of a significant resistance to the actions 
of insulin, indicate that these mitogenic effects are mediated by the  high 
circulating insulin levels exerting its action through the homologous IGF-I 
receptor. 
 MUTATIONS IN PPAR  GAMMA 
                      The nuclear receptor peroxisome proliferator-activated receptor γ 
(PPARγ) appears to play a vital role in both adipocyte differentiation and 
insulin action, thus denoting  the important interactions between these two 
phenomena .The mutation associated with this (dominant-negative and other 
types of  mutations)  result in the features of severe insulin resistance .these 
syndromes are characterised by partial lipodystrophy involving the  limbs and 
buttocks, with specific sparing of the adipose deposits of the abdomen and 
likewise  sparing the face
(38)
.This characteristic  lipodystrophy is explained by 
defect of the subcutaneous adipose tissue in the abdomen  to trap and store the 
free fatty acids in postprandial state . A Pro12Ala polymorphism in the PPARγ 
gene is found to be associated with better sensitivity to insulin .In general, the 
expression of PPARγ  is high  in the adipose tissue of obese individuals 
,however this is seen to be down regulated in individuals with a low-calorie diet 
(39)
. 
 IMPACT OF OBESITY ON INSULIN ACTION 
                     The proportion of  body fat in mammals is spread across a wide 
range , from 2% to 50% of  total body mass .Obesity or excess of  body fat, 
plays a significant role in the pathogenesis of IR  and  greatly elevates  the risk 
of developing type 2 diabetes  .Drastic hike  in the intake  of low-cost fat and 
simple carbohydrate calories have lead to the massive increases in occurrence of  
of overweight and obesity. 
                  Adipose tissue acts  as the body's main site  for storage of  energy , 
and it regulates the  insulin action on the entire body mainly through  the release 
of  free fatty acids and by the production of proteins derived from adipose 
tissue. These adipose derived proteins include the pro inflammatory peptides, 
and newer hormones which exerts a significant   effect  on  insulin action and 
the metabolism of glucose. 
 ADIPONECTIN :   
                            It’s a secretory protein that increases the sensitivity to insulin 
(40)
. Decreased levels of these hormones in circulation is seen to occur in 
conjunction with IR and obesity in humans and in experimental animals. 
(41)
 
Studies revealed a negative correlation between adiponectin levels and   
hyperinsulinemia  also with the extent of insulin resistance .Chronic  restriction 
of calories (which is said to improve insulin action)  results in an increase in 
levels of adiponectin .Furthermore, higher levels of plasma adiponectin are 
associated with a substantially decreased risk of development of type 2 diabetes.  
                       Additionally, suppression of the production of glucose  in 
hepatocytes  by the sub physiological levels of the hormone insulin is mediated 
by adiponectin. The ratio of the two oligomeric forms (HMW/ LMW) has 
recently been shown to correlate more clearly with action of insulin than the 
total amounts of the hormone in circulation. Pharmacologic activation of 
PPARγ with  thiazolidinediones increases adiponectin levels, the most striking 
effect is a selective proportional increase in the HMW form with close 
association with improved hepatic insulin action. 
 LEPTIN :  
                       Leptin is produced by a defect in the obesity gene and is 
produced from adipose tissue. The levels of circulating amounts of leptin 
correlates more clearly with insulin levels in fasting and proportion of body fat. 
Thus it’s appropriate to identify leptin as a marker of obesity and the syndrome 
of insulin resistance . Acute leptin administration produces an enhanced 
inhibition of glucose production in liver by insulin without affecting its 
peripheral action .
(42)
  
 
                 However chronic leptin administration induces metabolically 
favourable changes in body composition that include decreased visceral 
adiposity and reduced muscle accumulation of triglyceride 
(43)
. These changes in 
body composition induced by leptin are associated with an enhanced sensitivity 
to the various metabolic changes in skeletal muscle attributable to insulin. 
 
             
Figure 6 factors contributing to insulin resistance 
              
                  
                     These favourable effects on body composition and lipid storage 
may be due to leptin-induced stimulation of β-oxidation via activation of 
AMPK in muscle and liver. Profound leptin deficiency in is accompanied by 
impairment of T-cell immunity. Leptin influences the regulation of hormones in 
the HPO axis and affects the anterior pituitary hormones like prolactin, growth 
hormone, prolactin, and others as well. 
                 Leptin has anorectic effects which is mediated centrally and 
resistance to this mechanism occurs in the presence of nutrient excess 
(44)
. 
However, leptin was effective in increasing energy expenditure in obese 
individuals after a sustained weight reduction of ~10% of their previous body 
weight. 
 
RESISTIN    
                   Its a adipose tissue-specific hormone recently and is up regulated 
during adipogenesis and down regulated by treatment with a PPARγ   agonist . 
The IR produced by infusion of resistin was completely accounted for by a hike 
in the glucose production rate, suggesting that resistin has rapid inhibitory 
effects on hepatic rather than peripheral insulin sensitivity. Furthermore, few   
studies indicate an association between levels of resistin and BMI or with  
insulin sensitivity among humans 
(45)
, however no evidence exists to reveal such 
a connection. 
 
 OBESITY, INFLAMMATION AND IR 
                    There is mounting evidence indicating a more causal relationship   
between inflammation and insulin resistance and not a mere  correlative 
association. Epidemiologic data from several large studies have demonstrated 
an association between IR and systemic inflammation in both diabetics (type 2 
DM) and the non-diabetic populations 
(46)
. Adipose tissue produces many pro 
inflammatory molecules, including TNF-α, IL-6, TGF-β, C-reactive protein, 
MCP-1, and circulating levels of these “adipokines” are increased in obesity. 
Pro inflammatory chemicals derived from adipose tissue are found to produce 
systemic IR and also leading to the pathogenesis of various metabolic 
complications of obesity, including type 2 diabetes and atherosclerosis . 
                     TNF-α reduces the sensitivity to insulin and enhances the 
adipocyte lipolysis 
(47)
. Expression of TNF-α is increased in white adipose tissue 
in obese as well as insulin-resistant states. TNF-α activates NF-κB. Stimulation 
of production of various other cytokines is the main action of TNF –α. And 
these cytokines exert their action   directly on the muscle. 
                 Lipolysis is found to be increased by IL-6 and has been found to 
increase values of triglycerides and serum free fatty acids in obesity .  Further 
IL-6 produces insulin resistance at the cellular level in hepatocytes 
(48)
. Current 
studies indicate an impairment in insulin sensitivity produced by          the 
chemokine MCP-1. Aspirin treatment inhibits the phosphorylation of serine in 
of IRS-1 of the tumour necrosis factor-α treated cells. This is done by action 
upon the multiple serine kinases ,thus imparting  a beneficial role. 
                Obesity is associated with increased infiltration of macrophages into 
adipose tissue. With the onset of obesity, pre-adipocytes are stimulated to 
secrete the chemokine MCP-1, this is stimulated by secretion of very low 
amounts of TNF-α.MCP 1 is a chemoattractant specific for monocytes and 
macrophages 
(49)
.Adipocytes produce leptin in higher amounts ,which produces 
the transport of macrophages leading to their accumulation in adipose tissue. 
(50)
  
It also promotes the  adhesion of macrophages to endothelial cells. Adipocytes 
also produce colony-stimulating factor-1 (CSF-1). This CSF-1 is the primary 
moderator of macrophage differentiation and survival. Once the macrophages 
are activated they are present in adequate quantity in the adipose tissue. They 
act in conjunction with the adipocytes and other formed elements   to perpetuate 
a  vicious circle. This vicious cycle comprises of recruitment of macrophages 
and secretion of inflammatory mediators, ultimately resulting i  systemic insulin 
resistance. 
 
 
                  
Figure 7 obesity and insulin resisitance pathways 
              
                    The size of the adipocyte cell  is found to correlate 
significantly with dyslipedemia, markers of IR and risk for developing type 2 
diabetes . The amount of visceral fat mass, which  takes into account both   
omental , mesentric  and other intra-abdominal fat depots, is significantly 
correlated with the pathologies associated to obesity than is overall body 
adiposity . Proposed mechanisms for the negative metabolic effects of visceral 
fat include unrestrained lipolysis with increased circulating FFA levels, a 
specific increase in portal delivery of FFA, and unfavourable secretion profiles 
of adipose-derived proteins.  .catecholamines exert a stronger influence on the 
visceral fat cells by producing lipolysis, than the antilipolysis produced by 
insulin. This is the inverse of the process occurring in subcutaneous fat.
(51) 
                        
                         Furthermore, the portal vein receives the direct venous effluent 
from the visceral adipose tissue, leading to a high flux of free fatty acids into 
liver in centrally obese individuals. Increased hepatic delivery of fatty acids 
results in hepatic insulin resistance and in decreased insulin clearance, which 
leads to occurrence peripheral insulin resistance. This indicates the   presence of 
a “cross-talk” between adipose depots. It also reiterates the fact that the 
secretory mediators produced by visceral fat play a significant role in 
metabolism of  subcutaneous fat and in the onset of insulin resistance. 
 
INTRAMYOCELLULAR TRIGLYCERIDE ACCUMULATION 
                   Accumulation of triglyceride intramuscularly leads to the 
development of resistance to insulin action in the muscle irrespective of the 
person being obese or lean , or diabetic or non diabetic. In insulin-resistant 
persons who are obese, there has been a demonstrable impairment in the uptake 
and metabolisation of free fatty acids . This can be explained by the defect in 
carnitine palmitoyltransferase-1 (CPT-1) or the steps occurring further 
downstream in the fatty acid oxidation pathway. 
 
                  The rate of muscle fatty acid oxidation  is influenced by the levels of 
plasma insulin, delivery of free fatty acid and glucose .
(52)
  this is indicated by 
the  tissue  aggregation of  of malonyl-CoA. The levels of free fatty acids in 
circulation is increased in insulin-resistant individuals, also a concurrent defect 
in the metabolism of FFA occurring at the extramuscular level also contributes 
to insulin resistance. Thus the higher amounts of FFA delivered to the muscle 
along with an impairment in the muscle fatty acid oxidation have additive 
effects on the intramuscular triglyceride accumulation leading to the occurrence 
of IR in muscle in individuals with obesity and IR. 
 
INTRAHEPATO CELLULAR TRIGLYCERIDE ACCUMULATION 
                     Nonalcoholic hepatic steatosis (infiltration of fat in the liver) is a 
common observation in people with obesity. This may fall into any of the 
following stages of steatosis, steatohepatitis, fibrosis, and cirrhosis . Lean , non 
-diabetic, non-alcoholic  subjects who had fatty liver in liver biopsy had a 
impairment in the insulin -mediated depression of gluconeogenesis and 
reduction in glucose disposal  which is insulin-stimulated (by ~ 50%) and 
insulin resistance comparable to that of individuals with type 2 diabetes 
(53)
. 
                 Hepatic enhancement of FA oxidation was found leading to increased 
uptake of glucose in the peripheral tissues( insulin-stimulated ) even when 
associated with intra cellular triglyceride accumulation in the muscles. It has   
been considered that an unidentified factors secreted by the liver increases 
glucose uptake into skeletal muscle. 
ENVIRONMENTAL FACTORS RESULTING IN IR 
Medical conditions: 
                One of the first medical causes of insulin resistance to be identified 
was the presence of antibodies to insulin receptor (type B insulin resistance) IR 
is a component of chronic renal failure and  uremia , this insulin resistance is 
however found to  improve with dialysis.  The cause of the insulin resistance in 
renal failure is multifactorial. The reduction in muscle mass , impaired  physical 
activity, increased levels of  toxins of uremia, hormonal imbalances ( elevated 
growth  hormone and glucagon), altered lipid ratios and metabolic acidosis are 
considered to be possible mechanisms. 
                 Cirrhosis of liver is commonly  associated with abnormal glucose 
tolerance and insulin resistance. Elevation in circulating FFAs and insulin 
levels, both are proved to inhibit insulin action. 
                 Insulin resistance is a commonly  recognized problem in patients 
with several types of cancer, particularly malignancies of the gastrointestinal 
tract and pancreas . It has been proposed that inflammatory mediators contribute 
to this insulin resistance, particularly TNF-α and IL-6. 
Hormonal mediators: 
                  Insulin resistance has been documented in the presence of many 
syndromes of abnormal hormone levels, particularly states of hormone excess. 
The following hormones (epinephrine, norepinephrine, cortisol , glucagon, and 
growth hormone) play vital roles in opposing the  insulin action after 
hypoglycaemia. In Cushings syndrome hyperactivity of the hypothalamic-
pituitary-adrenal axis and that the enhanced cortisol secretion contributes to 
insulin resistance. 
                Increased levels of norepinephrine or epinephrine or both contribute 
to insulin resistance in phaechromocytoma. Growth hormone acts at multiple 
states to inhibit insulin actions. This includes suppression of the insulin receptor 
phosphorylation and its main signalling molecule, the  IRS-1, leading to the 
development of insulin resistance in acromegaly. 
SYSTEMIC EFFECTS OF NUTRIENT EXCESS 
                             Glucose toxicity refers to the inhibitory effects of chronic 
hyperglycemia on insulin secretion and action  . Hyperglycemia  induced insulin 
resistance includes- down regulation of the glucose transport system by 
hyperglycemia and a defect in insulin-stimulated glycogen synthesis. The 
desensitization of the glucose transport system induced by glucose could be 
prevented by glutamine analogues that inhibit glutamine : fructose-6-phosphate 
amidotransferase (GFAT)
(54)
, the initial and rate-limiting enzyme in hexosamine 
biosynthesis .Protein kinase C is activated by diacylglycerol ( a component of 
the intracellular component), the  increase in concentration of diacyl glycerol is 
found be dependent on glucose. The muscles when exposed to hyperinsulinemia   
PKC inhibitors blocked insulin desensitization by glucose. 
                            As discussed earlier insulin resistance is commonly associated 
with inappropriate suppression of oxidation of fatty acid . Similarly there exists 
a definite inverse correlation between the oxidation of glucose and lipids 
diabetic subjects who are obese. Elevated amounts of free fatty acids in plasma 
results in the down regulation of insulin signalling  occurring at the level of 
human skeletal muscles. Increase in the free fatty acid levels can also perpetuate  
inflammation. The high levels of fatty acids in plasma also lead to defective 
suppression of hepatic gluconeogenesis. 
 
OXIDATIVE STRESS AND AGING 
                       Activation of common stress-activated signalling pathways such 
as nuclear factor-KB, MAPK, and NH2-terminal JKinases ,stress-activated 
protein kinases(
56)
 by glucose and possibly free fatty acids leads to an 
impairment in insulin sensitivity and secretion. 
                       The final “environmental” factor that contributes to insulin 
resistance is   increasing age. The multiple factors associated with aging leading 
on to IR are higher fat mass especially the increase in visceral adiposity , 
elevated levels of inflammatory proteins in circulation, and an increase in 
accumulation  accumulation of triglycerides within the cells
(57)
. A consistent 
documentation about aging is that restriction of calories in a chronic fashion 
markedly improves survival and protects from developing IR
(58)
. Recent studies 
point that the reduction in mitochondrial functions associated with advancing 
age like that of oxidative phosphorylation , contributes to development of  
insulin resistance in the senior population. 
 
 
                    As reviewed above, insulin resistance occurs as a result of the  
complex interactions of genes, obesity, and “environment,” with the latter 
including nutritional and hormonal factors, as well as advancing age. And this 
insulin resistance plays a pivotal role in developing type 2 DM , atherosclerosis 
and the platelet dysfunction underlying all these conditions. 
        
Figure 8 inflammatory mediators in insulin resistance 
  
                      
 
PATHOLOGY OF MICROVASCULAR COMPLICATIONS 
                          
                       The classical triad of microvascular complications include 
retinopathy, nephropathy and neuropathy. Recent studies indicate that the 
pathological mechanism behind these complications is not entirely a 
microvascular insult but other factors also play a role. The occurrence of 
cellular dysfunction in the nonvascular tissues in the early stages of DM 
reiterate this fact. The question as to why only certain tissues in particular are 
affected has to be answered. 
 
 
THE CHANGES IN VASCULATURE 
                           The vascular cells undergo growth and apoptosis preferentially 
in diabetes. There is a preferential activation of the apoptotic pathways in the 
pericytes of retinal microvasculature , in the renal capillaries  and the micro 
capillaries of heart .While  there is activation and proliferation of  microvessels 
in proliferative retinopathy, and atherosclerotic lesions. The chemical mediators 
of the apoptotic pathways are hydrogen peroxide, NF κ B, JNK1(59). 
                      The thickening of basement membrane forms the main 
pathological feature of microangiopathy ,  and this is a universal phenomenon 
occurring in both the vascular and nonvascular structures. The basement 
membranes of the capillaries in retina normally thickens with age , this however 
occurs at an accelerated phase in diabetic population. In renal pathology, there 
is an expansion of the extracellular matrix which is seen as a thickened GBM, 
mesangial expansion and tubulointestitial fibrosis.
(60)
 An increase in synthesis 
and reduced degradation of the extracellular matrix proteins is seen as the 
underlying defect. Diabetics display an overexpression of collagen type 4 and 
fibronectin. Endothelial dysfunction is a very important pathological process in 
microvascular changes of diabetes and it is dealt in detail in subsequent 
chapters. 
TISSUE SPECIFIC VASCULAR CHANGES 
                                The changes in retinal microvessels include basement 
membrane thickening , increase in the vessel permiability, destruction of 
pericytes and all these leading to microaneurysm formation. These changes lead 
to occlusion of the vessels, reduction in retinal blood flow, angiogenesis, 
hemorrhage  and finally retinal detachment. The normal ratio of pericytes to 
endothelial cells in retinal capillaries is 1:1
(60)
  , in diabetics there is steep drop 
and the ratio falls to 1:10 in moderate NPDR. This obvious lack of pericytes 
leads to the formation of micro aneurysms
(63)
. The presence of relative hypoxia 
in retinal vessels leads to the activation of growth factors like VEGF, PDGF and 
placental growth factor
(61)
. 
                             In nephropathy ,acute hypertrophy of the glomeruli occurs in 
the initial stages of diabetes, this along with the increase in mesangium leads to 
gross decrease in the filtration area. Kimmelstiel and Wilson
(64)
 was the 
first to demonstrate the thickened GBM in diabetic kidneys. An 
elevated intra glomerular pressure and permeability leads to the 
excretion of proteins of  44 -150 kDa .the increased GFR and 
proteinuria in initial stages of DM can be reversed with i ntensive 
insulin therapy.
(65)  
                      Peripheral neuropathy is quite common in diabetics 
and is present in > 50 % of individuals. The abnormality can be 
accounted to changes in the neurons secondary to hyperglycemia or 
ischaemia produced by reduced neuronal blood flow
(66-67)
. 
Narrowing of capillary lumen and activation of protein kinase C has 
been demonstrated. 
                   Changes in microvessels of the heart can be held 
responsible for the increased occurrence of chronic heart failure in 
diabetics. The reason behind this increased incidence is mostly 
diastolic dysfunction and reduced formation of collaterals following 
myocardial ischaemia(68) .  The relative density of capillaries in 
myocardium of patients post infarction was reduced in  diabetics than 
the normal control subjects.  The cardiac neovascularisation and 
collateral formation is dependent on the homeostasis of multiple pro 
and anti angiogenic factors ( VEGF, PDGF,FGF, angiopoeitins ,etc)  
. An imbalance in this milieu is evident in diabetes. Accumulation of 
extracellular matrix can lead to cardiac fibrosis   thus resulting in 
diastolic dysfunction. 
 
METABOLIC ALTERATIONS AND ITS INTRACELLULAR 
CONSEQUENCES 
                          Hyperglcemia is considered to be the prime factor for the 
development of  vascular complications ,however the evidence proves to be 
contradictory as there is no apparent reduction atherosclerotic complications in 
patients with lower blood glucose levels. The abnormalities in diabetes are 
attributed to the abnormally high uptake of glucose in the cells and elevated 
intracellular glucose concentrations. This is avoided in tissues exhibiting insulin 
resistance. Thus IR seems to be of beneficial effect by reducing intracellular 
concentrations of glucose. Thus the next step was that organs incapable of this 
mechanism of IR where prone to the complications of diabetes (111). This is 
seen in endothelial cells which express GLUT-1 receptors ( they  do not respond 
to insulin )  and lack GLUT 2-5. In the setting of hyperglycemia the smooth 
muscle cells of the blood vessels are capable of down regulating GLUT-1  
however the endothelial cells are incapable of doing so , thus making them more 
susceptible to complications. 
 
INTRACELLULAR REDOX STATUS 
                       
                       The imbalance between the reactive oxygen species 
and antioxidant pathways result in oxidative stress .Abnormal 
metabolism of glucose or defect in the enzymes not associated to 
glucose metabolism is considered to produce this imbalance. 
Glutathione in its reduced form is found to be depleted in the 
diabetic population (119).Organ systems developing microvascular 
complications are found to be affected by oxidative stress and 
antioxidant therapy helps in the prevention of organ d amage. 
Cellular dysfunction is produced by means of production of 
advanced glycosylated end products, breakage of DNA, PARP 
activation and promoting other stress induced pathways ultimately 
leading to apoptosis.  
 
 
 
ATHEROTHROMBOSIS – EVOLVING CONCEPT 
             
            
                       Atherothrombosis, is defined as disruption of atherosclerotic 
plaque with super imposition of thrombosis. It’s the leading cause of mortality.  
Atherosclerosis is a widespread systemic process and starts early in the first 
decade of life progressing asymptomatically into adult life. It clinically 
manifests as CAD (coronary disease), cerebrovascular disease,transient 
ischaemic attack (TIA),stroke, and peripheral arterial disease . It’s often 
considered as a single pathological entity affecting various vascular territories. 
Atherothrombosis is a diffuse process affecting the arterial treeof systemic 
vasculature .The tunica intima of both medium and large sized arteries is 
involved ( the tunica intima of the aorta, coronary vessels, carotid arteries and 
peripheral arteries as well ). The plaques of atherosclerotic vessels are mainly 
comprised of
(68,69) 
: 1)extracellular rmatrix components   ( proteoglycans 
,fibroelastic proteins, collagen) 2) phospholipids and esters of cholesterol ; 3) 
mononuclear  inflammatory cells  (T lymphocytes, macrophages, 4)pro 
thrombotic factors  (platelets and deposits of fibrin ). 
 
 
                         Endothelial dysfunction , a widespread systemic pathological  
process is considered as the precursor to atherothrombosis. Two major  
hypotheses where proposed in the 19
th
 century- von Rokitansky proposed the 
incrustation hypothesis and Virchow proposed the lipid hypothesis. They 
concentrated on lipid accumulation ,fibrin deposition and formation of 
extracellular matrix. It was Virchow who coined the term endarteritis deformans 
and linked inflammation  to the process.  The initial stages of the atherosclerotic 
process is characterised by chronic inflammation and   retention of lipoprotein. 
The inflammatory process leads to the rupture of plaque and thrombosis 
(70)
. All 
these hypotheses can be compiled together to form a single term – 
Atherothrombosis. 
 
 
PHASES OF ATHEROTHROMBOSIS 
 
                          
                          According to the AHA classification the progression of the 
atherosclerotic plaque can be  divided into 5 pathological phases with 
significant relevance clinically as well. 
 
Phase 1 (early stage ).  These   lesions   most commonly seen in 
 
young adults are small  and can be further divided into 3 types : 
 
Type I : the lesions consist of foam cells formed from macrophages , containing  
 
               droplets of   lipids  
 
Type II : they are comprised of vascular smooth muscle cells, mononuclear cells  
 
             ( macrophages ) and extracellular deposits of lipids. 
 
Type III : they are made of connective tissue surrounding  smooth muscle cells 
 
             and deposits of  lipid . 
 
Phase 2 (advanced stage).   In this stage though not essentially stenotic  , are 
prone to rupture due to increased content of lipid , presence of  
inflammatory process and a relatively thin cap of fibrous tissue.  They are 
further classified   morphologically into two forms: 
type IV:  they are charecterised by confluence of cells which is rich in lipid       
               derived from the extracellular compartment and normaly appearing                   
                intima forming the outer cap 
type Va: lesions appear as an acquired fibrous cap  covering extracellular 
               lipid core.These lesions progress into the acute stages of phase 3 and 4 
                    
         This is a cross section of coronary artey with an occlusive thrombus overlying an atheromatous plaque. 
 
Phase 3. They are the complicated forms of type 4 lesions. They evolve from  
                ruptured or eroded lesions, and form non-obstructive, mural thrombi.       
                 This process is usually clinicaly silent but on rare occasions present   
                 as angina
(70)
. 
Phase 4.  they are also a complicated version of type 4 lesions, presenting as a   
                thrombus  which is fixed or that which causes reccurent occlusions. 
                This  stage of atherosclerosis has clinical manifestations  and presents   
                as an acute coronary syndrome, certain lesions however remain silent   
                
(71)
. About 2/3 rd of  acute coronary syndromes are produced   
                when occlusion in produced by thrombus in a plaque that is not   
                stenotic 
                 However in the remaining one third of conditions , are produced by 
thrombus occluding a plaque that is stenotic .
(70)
 In the third and fourth phases 
of plaque formation the connective causes organisation of the lesion leading to a 
thrombus that is stenotic or produces occlusion or complete fibrosis.  
 
Phase 5. They are divided into two types Vb which is calcific 
              And Vc  which is fibrotic. Both these lesions may produce  angina        
              chestpain .However,if  there is occlusion and an episode of myocardial   
              ischaemia the tissue is then protected by the formation of collateral  
              vessels.in such a case the lesion is found to be clinicaly silent.  
 
                           
Figure 9 atherosclerosis stages 
                
 
                                       EARLY ATHEROTHROMBOSIS 
 
ENDOTHELIAL DYSFUNCTION 
                          The endothelium is considere as a dynamic structure, having 
autocrine and paracrine functions. It regulates anti inflammatory  ,mitogenic,  
and contractile processes of the vasculature, also produces  regulation of  the 
hemostatic activities happening inside the vascular lumen . The single most vital 
molecule responsible for the entire process is nitric oxide (NO ). Dysfunction of 
the endothelium leads to  reduction in synthesis of NO, which paves way for the 
lipoproteins in circulation to enter and undergo  oxidation. Lack of NO also 
favours the diapedesis  and internalization of macrophages, favours 
inflammatory processes, proliferation of smooth muscle cells and  deposition of 
ECM,  also favouring vasoconstriction all favouring  the formation of 
intraluminal prothrombotic state
(72)
. 
                        Dysfunction of the endothelium is universally considered as the 
earliest  step  atherothrombosis. An alteration in the blood flow pattern either a 
reversal of flow or occurrence of shear stress of oscillating type ( mainly  at the 
areas of vascular bends or bifurcations ) result in this dysfunction of 
endothelium. Apart from the shear stress, the presence of   biohumoral risk 
factors like dyslipedemia , advanced glycation end products ,the  irritants found 
in  tobacco smoke , immune mediated complexes and vasoactive amines in 
circulation contribute to endothelial dysfunction. The endothelium responds to 
the shearing stress  by way regulating the suppression or activation  of  various  
genes .thus it leads the increased formation and release of cellular adhesion 
molecules (CAMs) from the family of selectins (E selectin  and P-selectins). 
They in turn accelerate the monocyte margination  and  its adhesion to the 
surface of the activated endothelium.  These proteins of cell adhesion in the 
vascular compartment favour the internalization of  mononuclear cells adhered 
to the vessel wall into it thus paving the way  to  atherogenesis. Clinical studies 
have demonstrated an association between the elevated cellular adhesive 
molecules and an increased risk for cardiovascular derangements. 
 
 PROTEOGLYCANS AND LIPOPROTEIN TRANSPORT    
                             The entry of  Low-density lipoproteins into the tunica intima 
of the vessel wall is facilitate by the interaction between the proteins of 
extracellular matrix (proteoglycans, collagen, fibronectin )and apo B lipoprotein 
fraction (49) . Proteoglycans are biochemically composed of a core component 
formed by  protein and a glycosaminoglycan chain (a long chain carbohydrate ).  
These proteoglycans and the proteins of ECM   are present between the internal 
elastic lamina and the  endothelial cell’s basement membrane  . The critical step 
in early atherosclerosis is the interaction between oxidized LDL and 
proteoglycans .the other lipoprotein playing an important role in atherosclerosis 
is HDL. Its primarily called as the anti atherogenic lipoprotein, HDL brings 
about  reverse cholesterol transport ,i.e transport of cholesterol from  the arterial 
wall, especially from lipid-laden macrophages inspite of its protective effects, 
individuals with high HDL levels can still present with acute coronary 
syndromes, this can be attributed to the elevated levels of HDL3 rather than  
HDL2. 
 
Innate and adaptive immune response to auto-antigens 
                     Inflammation is found to play an important role in 
atherothrombosis and the focus has now shifted on the immune system. innate 
and adaptive immune responses greatly influence the development of 
atherosclerosis 
(73)
. The first step in the immunological response to organisms is 
by innate immunity .The toll-like receptors(TLR) and scavenger receptors form 
the critical receptors of innate immunity in atherosclerosis  
(74)
. 
                  In the first step of this immune process  there occurs the  uptake 
of LDL in its oxidized form by SR-A and CD-36 (the scavenger receptors) and 
then the production of foam cell from  a macrophage.
(74)
It results in the 
activation of  NF κ-B a nuclear transcriptional factor, which in turn initiates a 
strong chemo attractant cycle leading to migration of monocyte and macrophage 
/foam cell formation .These activated macrophage/foam cells produce cytokines 
which activates the  neighbouring smooth muscle cells, leading to formation of 
extracellular matrix and fibrosis . 
 
                   The innate immunological response in its second step, the Toll like 
receptors play a significant role. Stimulation of TLR4 results in activation of 
NF-kappa-B and elevated synthesis mRNAs of numerous cytokines 
(75)
. 
Activation of TLR4 in adventitia augments the formation of neo intima. TLR4 
is involved both in the initiation, progression and expansive remodelling of 
atheromatous plaque. 
            
                   The adaptive immunity has a more organised response , however it 
takes several weeks to initiate the response is characterised by generation of  
immunoglobulins, T and B cell receptors  capable of recognising foreign 
antigens. 
 Figure 10 endothelial dysfunction 
 
MECHANISM OF CALCIFICATION 
                        Calcification in atherosclerosis is due to deposition of both 
hydroxyapatite and organic matrix .This organic matrix is comprised of type I 
collagen and  other non-collagenous bone-associated proteins (NCPs) 
(76)
. 
Collagen produces crystal accumulation ,this potentiates mineralization  
occurring inside  the vesicles of extracellular matrix. Thus dystrophic 
calcification is considered now as an active, organised entity rather than a mere   
passive calcium accumulation .  
                       The important non collagenous proteins, associated with 
calcification of vasculature include osteopontin (OPN), osteonectin, 
osteoprotegerin, and matrix Gla protein. The most extensively studied among 
these is osteopontin (OPN).  OPN was found to be expressed  in  atheromatous 
macrophages , adventitial cells and the smooth muscle cells of the aortic wall.  
 
ADVANCED ATHEROTHROMBOSIS 
                            The prolonged exposure to a pro-atherogenic milieu increases 
the   chemotaxis of mononuclear cells , lipid accumulation, formation of 
necrotic core and fibrous cap – thus progressing to advanced atherosclerosis. 
Expression of metalloproteinase and inflammation results in plaque rupture 
occurring at the shoulder of   large plaques with high lipid content .Newer 
structural and functional alterations have been identified, eccentric growth of 
the  plaque with an enlargement of the vessel wall which is compensatory. This 
process is known as vascular remodelling, its associated with neovascularization 
vasa vasorum resulting in an expansion of the lipid core   and occurrence of  
haemorrhage within the plaque. 
 
ECCENTRIC VASCULAR REMODELLING 
                       The growth of an atheroma eccentrically within the inner   
constituents  of the vessel wall  prior to formation of luminal obstruction is also 
considered as vascular remodelling.  The study by Glagov et al 
(78)
, has found   
remodelling as a consistent factor  in atherosclerotic lesions of the acute 
coronary syndromes. 
                           The remodelled atherosclerotic plaque is found to consist of a 
core rich in lipids, minimal smooth muscle cells with numerous macrophages 
infiltrating the plaque .Rather than the concentrical growth within the lumen as 
expected the eccentrical growth triggers crucial alterations in the tunica media 
and adventitia of the vessels. The hyperactivity of metalloproteinases destroys 
the Internal elastic lamina, forming the crucial step of remodelling. Recent 
studies have demonstrated the break in the IEL as an independent 
 predictor of rupture of plaque . Furthermore tunica media showed increased 
levels of  inflammation, fibrosis, and atrophy. The  non-ruptured plaques had 
less of inflammation of the adventitia than that of the plaques undergoing 
rupture 
(77)
. 
 
VASO VASORUM NEOVASCULARISATION 
                           The adventitial vasa vasorum is responsible for  nourishment of  
blood vessels by way of  diffusion of oxygen from the vascular lumen . When 
the thickness of the vessel wall is greater than the appropriate distance required 
for effective oxygen diffusion then there is a proliferation of  vasa vasorum into 
the internal layers of the vasculature ( where it is usually absent ). This 
proliferation of vaso vasorum is driven by cytokines produced by the 
Macrophages which are in turn attracted by oxidized LDL. 
                             There are 2 anatomical forms of vasa vasorum;  the first-order 
which proceed in a longitudinal fashion into the vessel lumen and the vasa 
vasorum of second-order  are circumferentially  arranged around the wall of the 
vessels. 
                          However, in the setting of  atherosclerosis the  vasa vasorum 
proliferates, causing a significant neovascularization of the tunica media and 
they are seen proliferating in the direction of the atheromatous lesion rich in 
lipids. The newly formed microvascular content was higher in the plaques of the 
human aorta undergoing rupture than those of the unruptured ones.similarly 
recent studies point to an increased content of new vessel formation in the 
atheromatous vessels of the diabetic population. 
(78) 
the plaques with a reduced 
lipid content and more of fibrocalcific lesion are called as regressive lesions. 
These regressive lesions had a relatively low neovascular content than the lipid 
rich ones . Thus the vasa vasorum are considered to play a prominent role in the 
reverse lipid transport. During reverse lipid transport the microvessels and the 
outer layers of the vascular wall undergo the aforesaid process of regression. 
This has been proven in animal studies with plaque regression. . 
 
PLAQUE RUPTURE 
                         Two mechanisms are attributable to plaque rupture they may act 
independently or in conjugation to produce rupture. Firstly, it is attributed to the 
to physical forces and occurs most commonly in the thinnest areas of the  the 
fibrous cap ,the site which is  heavily infiltrated by foam cells, and thus the 
most weakest .For eccentric plaques, this weakest spot occurs at  the shoulder or 
at a point  between the vessel wall and the plaque
(79)
. Vulnerability of the plaque 
to rupture is said to depend on multiple components.  these include the stress on 
the vessel wall exerted  circumferentialy  and  cap fatigue; the  consistency ,size 
and  location of the core of atheromatous lesion; and finally the characteristics 
of  blood flow ,most importantly the flow impact  on 
the proximal part of the plaque (i.e. the plaque angulation ). 
  
                     The second  of the mechanisms involves a process which occurs 
inside the plaque leading to its rupture in the  macrophage and mast cell rich  
. These macrophages and mast cells within the plaque initiate proteolysis and 
phagocytosis resulting in the degradation of ECM. According to a human study 
the quantity of few matrix metaloproteinases and their inhibitors  correlate with 
the extent of atherosclerotic process . The  macrophages in order to shield the 
blood vessel wall from lipoprotein accumulation undergo  apoptosis. 
(80)
 The 
apoptosis produces membrane microparticle shedding and the consequent 
exposure of cell surface  phosphatidylserine( the prime contributor for 
formation of  thrombosis after rupture of plaque. 
(80)
 It is now clear that 
apoptosis is  the common link  between thrombosis and inflammation. 
 
PLAQUE DEPENDENT THROMBOGENIC SUBSTRATE 
                    The arterial site thrombogenicity is determined to the exposure of a 
thrombogenic substrate. Lipid-rich plaques are found to be the most 
thrombogenic among all others. Tissue factor, is the glycoprotein that  initiates 
the extrinsic clotting cascade and plays a key role in   regulation of 
hemostasis,coagulation,  and thrombosis .  Tissue factor forms a complex with 
factors VII/VIIa with immense affinity; these Tissue Factor/VIIa complex in 
turn activate 
factors IX and X, which ultimately results in  generation of thrombin .The  
presence of  TF  in apoptotic macrophages, reiterates its role in ACS .In 
addition, by inhibiting the TF using  r-tissue factor pathway inhibitor resulted in 
decreased formation of acute thrombus among the plaques rich in lipids . This 
further substantiates the vital part played by Tissue Factor in thrombosis 
formation in coronary arteries. 
 
RHEOLOGY AND THROMBOSIS 
                         The  other important factors determining the thrombogenic 
potential  at the site of arterial disruption is the extent of  of stenosis produced  
by the plaque rupture and the thrombus overlying it. Thus, degree of narrowing 
modulates the platelet deposition after plaque rupture . The geometrical changes 
increases deposition of platelet , however a sudden increase in thrombus size 
may accentuate the stenosis and lead to   thrombotic occlusion. 
 
 SYSTEMIC PROCOAGULANT ACTIVITY 
                         The two major pathways accountable for pro-coagulant activity 
are factors affecting the coronary arteries and the tissue factor in circulation. 
Atherogenic dyslipedemia smoking, hemostasis, hyperglycemia and  various 
other factors  are linked to the elevated  blood thrombogenicity   As seen earlier 
levels of increased  LDL cholesterol are found to increase the thrombogenic 
potential of blood  and favours the proliferation of thrombus under specific 
rheological conditions . Smoking increases the release of catecholamine, 
potentiates activation of platelets  and elevates the fibrinogen levels
(81)
. The 
increased incidence of sudden cardiac deaths can be attributed to catecholamine 
-dependent effects .The platelets of the diabetic people are hyper-reactive  and 
have increased aggregation potential and  also display an array of activation-
dependent adhesion proteins .The activation of interactions between  leukocyte 
and platelet  results in the secretion of tissue factor and activation of  thrombin. 
The levels of Tissue Factor in circulation  is found to correlate with increased 
thrombotic potential in people with Acute coronary syndrome and chronic 
CAD. 
                        There has been a demonstrated increase in microparticles with 
increased TF activity originating from monocytes, this indicates the existence of 
a causal relationship between pro coagulant activity of the plaque and the 
microparticles shed from the membrane surface. Elevated levels of CRP has 
also been observed, whether the higher levels of CRP are due to the 
inflammatory mediators of the blood or that released from the plaque is still 
unclear. Whether it is a biologically active element in the process of plaque 
development or thrombus formation is also questionable.  Recent experiments 
indicate to  CRP being the cause for activation of  monocyte and endothelial 
cells in vessel. 
 
DETECTION OF ATHEROSCLEROSIS 
                           Imaging techniques help in detecting subclinical pathologies 
and may also serve as a surrogate technique thereby is in the improvement or in 
complementing the assessment of cardiac risk. Ultrasound examination is used 
to measure the of the thickness of aorta and carotid arteries , as well as 
qualitative and quantitative examination of the atherothrombotic plaques. A 
heterogenous plaque which is hypoechoic on ultrasound is indicative of  lipids  
 or haemorrhage within the plaque. Likewise a plaque that is homogenous and   
hyperechoic indicates fibrosis..The intima-media thickness of large- and 
medium-size arteries is measured by  Real-time B-mode ultrasound, especially 
the carotid, femoral, or radial.  Presence of carotid and aortic atherosclerosis 
indicates the concomitant presence of coronary artery involvement . A strong 
correlation was noted between AHA classification and the MRI images. The 
variation in the maximum thickness of coronary vessel wall of normal as well 
atherosclerotic arteries was found to be significant statistically,This was done 
by performing  high resolution black-blood MRI 
 
                         The blood pressure is measured in both the brachial arteries and 
the two posterior tibial arteries as well as the dorsalis pedis, for calculation of 
ankle-brachial index. Ankle-brachial index values when low (<0:90) are 
suggestive of a peripheral arterial disease. Furthermore,progressively decreasing 
trend of ABI  values points to a critical obstruction. The presence of a 
generalised systemic atherosclerosis is indicated by the lower levels of ankle 
brachial index. 
 
 
BIOMARKERS FOR ATHEROSCLEROSIS 
                       A selected group of  biochemical parameters are  said to indicate 
the presence of atherosclerosis, however their specificity is questionable.there is 
constantly increasing evidence that minimalistic elevation of CRP is predictive 
of adverse vascular processes in asymptomatic , healthy adults.Biomarkers in 
atherothrombosis can be grouped as  Inflammation markers – comprising of      
interleukins , CRP, amyloid A, CD40 ligand, cellular and vascular adhesive 
molecules and the second set as markers of thrombosis – v WF  ,fibrinogen,      
PAI- 1and prothrombin fragment 1 and 2.
(82) 
 
             Atherothrombosis is a widespread ,systemic disease where the main 
players are deposition of cholesterol,inflammatory process and formation of 
thrombus. This process is clinicaly not evident in the early stages and subjects 
are asymptomatic and presents dramatically with the formation of thrombosis 
and its complications.the five main stages of the disease process is dealt in 
detail in subsequent pages.advanced stages and coplex lesions are characterised 
by the presence of formation of new micro vessels and hemorrhages within the 
plaque. The circulating  Tissue factor, considered the strongest trigger of the 
coagulation cascade, plays  a vital role in determining the thrombogenic 
potential of the plaque.The microparticles of tissue factor in circulation are 
found to be in association with the monocytes thus completing the  link between 
inflammation,rupture of  plaque  and thrombogenicity. 
  
                                                       PLATELETS          
                             
                        Platelets are discoid, fragments of cell lacking a nucleus that are 
formed by cleaving from the bone marrow  megakaryocytes .Maintaining the 
hemostasis , formation of the primary hemostatic plug (which is the first step 
following endothelial damage)  and providing an active  surface for the 
recruitment and concenteration of coagulation factors are the main functions of 
the platelets.  A brief overview of the hemostatic processes is required for better 
understanding of the pathological basis of pro thrombotic state in diabetes. 
                     Following a vascular insult the platelets come in contact with the 
extra cellular matrix components and its proteins , they then undergo change in 
shape, adhesion to the endothelium, secretion and the release of granular 
content and finally aggregation . 
 
  
•  
   
  The adhesion of platelets to the extracellular matrix is mainly regulated 
by the von Willibrand factor , which bridges the platelet surface proteins 
mainly the Gp-Ib to the collagen. Though the platelets have the capacity to 
adhere to various other molecules in the ECM their interaction with  von 
Willibrand factor is essential to counteract the high shearing forces of the  
blood column. 
                     
Figure 11 adhesion and aggregation of platelets 
 
 
  
                             
                     Adhesion is immediately followed by the secretion or release 
of both the type of granules in the platelets.The platelet cell surface 
receptors undergo binding with various agonists leading to 
phosphorylation of the intracellular proteins and produces the 
degranulation of platelet contents. The components of the dense granules 
of pletelets namely calcium and ADP ( produces a strong  activation of 
aggregation ) play a vital role in the coagulation cascade and their release 
therefore forms a critical step. The platelets after activation express 
negatively charged phospholipids (especially phosphatidylserine) on their 
surfaces. They inturn bind to calcium and act as important sites of 
nucleation required for the organisation of coagulation factors and its 
complexes. 
 
  
 Aggregation : 
                                     Adhesion and release of granules is followed by 
aggregation of platelets.  Apart from ADP thromboxane A2 a potent 
vasoconstrictor is a critical stimulus that is required for the amplification 
of platelet aggregation,  all of these mechanisms result in the formation of 
the primary hemostatic plug. These initial processes are reversible , but 
the simultaneous activation of the coagulation cascade produces  
thrombin, which results in stabilisation of the primary hemostatic plug 
through 2 mechanisms. In the first process thrombin binds to a pecific 
activated receptor on the platelet surface , this is compounded by the 
effects of thromboxane A2 and ADP propagating firther aggregation.the 
next step is the contraction of platelets resulting in a stonger and tight 
bond forming the secondary hemostatic plug.later fibrin is formed from 
fibrinogen leading to the completion of process.  
 
 Fibrinolysis                  
    
                     Alongside the coagulation cascade a fibrinolytic process is 
also initiated that regulates the clot size. Plasmin is the main moderator of 
this fibrinolytic process , wherein it is responsible for breaking down of 
fibrin from its complex polymerised form. The end products of this fibrin 
breakdown have a weak anticoagulation action. The enzymatic breakdown 
of the precursor plasminogen results in formation of fibrin, this can be 
either due to factor XII mediated pathway or through the plasminogen 
activators . the key molecule among the plasminogen activators is the 
tissue plasminogen activator or tPA. Its released by the endothelium and is 
highly efficient when bound to fibrin. 
                        
 
                    The activation of the anti fibrinolytic pathway by the 
endothelium results in finetuning this balance. This is achieved through 
the action of plasminogen activator inhibitor (PAI); which causes the 
inhibition of tPA and thus produces a pro coagulant effect. Thrombin and 
few other cytokines facilitate PAI production, thus explaining the 
increased thombotic potential in inflammatory states.  
 
 
 
THE EFFECTS OF DIABETES ON PLATELETS 
 
 
 
                                 Insulin resistance acts as a common denominator in all 
individuals with type  2 diabetes. This insulin resistance coupled with defects in 
insulin action creates a milieu of platelet dysfunction conducive to the 
complications of  diabetes, both micro and macrovascular. The resistance to 
insulin stimulated uptake of glucose which forms the common precursor to 
diabetes and its vascular complications is considered as a multisystem disorder 
affecting  various metabolic and cellular pathways. Genetics, advancing age , 
physical inactivity and obesity are the contributory factors to insulin resistance.  
 
 
                        Defining insulin resistance merely as a defective regulation of 
glucose utilization grossly undermines the numerous other myriad effects 
produced by   defective insulin action .The more  appropriate  definition  would 
be “the metabolic state in which the measured  tissue response  to insulin is less 
than that expected for the apparently available  insulin.” This response is 
applicable  to metabolic fuels ,the effects of insulin on smooth muscle, 
endothelium, platelet function, erythrocyte function and neuropeptide secretion 
.prothrombotic  state is a recent addition to the insulin resistance syndrome .the 
pattern of coagulation dysfunction in IR is characterised by increased propensity 
for thrombosis and retardation of thrombolysis. Elevated levels of Plasminogen 
Activator Inhibitor 1 (PAI -1), fibrinogen and intrinsic platelet abnormalities are 
seen in Insulin Resistance. 
 
 
 
 
INSULIN RESISTANCE   AND   PROCOAGULANT  STATE 
 
                       
                        The coagulation cascade in IR is associated with abnormalities of 
 
platelet aggregation , adhesion , abnormal levels of  vWF , factor VIII,  
 
 thromboxane ,tissue plasminogen activator, fibrinogen and PAI-1. The  
 
European Concerted Action on Thrombosis Study identified the association  
 
between the components of IR and hemostatic factors. Higher levels of  
 
fibrinogen,PAI-1,vWF,tPA and prolonged clot lysis time was found to  
 
correlate with elevated levels of circulating insulin.  
 
  
                        There was a strong and  consistent correlation between high PAI-
1 and increased insulin levels and  decreased insulin sensitivity.
(83)
Insulin ,pro-
insulin and split products of insulin  also correlated with high PAI-1 levels 
(83)
. 
Likewise pro-insulin was associated  with elevated fibrinogen levels in subjects 
with IR. Thus the two prime  determinants of plaque formation ( fibrinogen, 
PAI-1) are related to high  circulating levels of insulin and its precursors.  
 
 
 
 
 
DIABETES, PLATELET, ATHEROSCLEROSIS 
 
                               
                        An increased intravascular thrombus formation and depressed 
fibrinolytic  activity contribute to atherosclerotic plaque production in diabetes 
mellitus. One of  the metabolic  derangements of insulin resistance syndrome is 
atherogenic  dyslipedemia- increased VLDL and small LDL particles with 
decreased  HDL .This atherogenic phenotype of IR is found to precede the 
occurrence overt  diabetes by many years. The higher levels of PAI-1 is found 
to have a positive  correlation with BMI and fasting plasma insulin in type 2 
diabetic  individuals .  
                   Similarly elevated triglyceride levels had a positive correlation in 
non-diabetic obese subjects. Physical activity and weight reduction brings down 
hyperinsulinemia and IR which in turn reduce PAI-1 levels thereby increasing 
fibrinolytic activity. This explains why vascular complications are common in 
obese than non-obese diabetics
(84)
. Thus the reason for reduced fibrinolytic 
activity in diabetic id due to elevated PAI-1
(88)
 which inhibits the  breakdown of  
plasminogen to plasmin. 
 
 
 
PLATELET AND EDOTHELIAL CELL INTERACTION 
 
                          Vascular damage endothelial injury, plaque rupture leading to  
 
aggregation and adhesion of platelets at the site , form the critical step in  
 
macrovascular complication of atherogenesis.The endothelium of healthy  
 individuals constantly release prostacyclin (PGI 2) and NO    which  
 
 prevents platelet aggregation and adhesion. At the site of endothelial injury in  
 
response to plasma thrombin , serotonin released from platelets, bradykinin,  
 
PDGF, IL2 and ADP there occurs an increased production of PGI 2 and NO.  
 
This negative feedback loop limits the formation of platelet plug and                 
 
de-endothelization.           
 
 
                            
                        Normally  prostacyclin binds to G protein receptor on the  
 
platelet surface leading to stimulation of adenylate cyclase enzyme. G protein  
 
inhibitory (G1) for adenylate cyclase is linked to α2 adrenergic receptor, which  
 
is capable of binding to epinephrine. NO directly diffuse across the plasma  
 
membrane and activates guanylate cyclase enzyme. Thus both the inhibitory  
 
pathways producephosphorylation of c-AMP and c-GMP dependent protein  
 
kinases resulting in inactivation of platelets and thus prevents their aggregation.   
 
 
                 Studies have demonstrated a reduced synthesis of vascular PGI2 and 
reduced release of NO in diabetic models thereby contributing to increased 
platelet activity. Apart from the reduction in synthesis  ,a reduction in sensitivity  
of platelets to anti-aggregatory molecules have also been demonstrated in 
diabetics. Platelets respond to a lesser degree to Prostacyclin and Nitric oxide in 
diabetic individuals.
(84) 
                   
Figure 12 endothelial mediators ,NO,PGI2 
 
                        
 
 
 
 
   Various mechanisms have been proposed for this reduced sensitivity of  
 
platelets, the concepts are discussed below. 
 
Impaired PGI 2 receptor activity 
 
 Modesti et al (85) showed that platelet in diabetics had normal levels of  
 
PGI2 receptors. Thus the problem was considered to be further  
 
 downstream 
 
 Livingstone et al(86)  found a decrease in the levels of G1 ( the  
 
glycoprotein for inhibitory pathway) in platelet membrane of diabetics.  
 
Thus it resulted in reduced stimulation of adenylate cyclase in response to  
 stimulation by PGI2 . 
 
 Bon et al (84) demonstrated a decreased  c-AMP response in obese insulin  
 
 resistant individuals tha non-obese subjects. The exact  underlying  mechanism  
 
 is still unclear. 
 
 Another study demonstrated a decrease in level of  G protein stimulated  
 
     platelet phospholipase C activityresulting in enhanced aggregation in  
 
     response to thrombin. 
 
 In type 2 diabetics ,genetic anomalies lead to inactivity of G proteins ,  
 
produced by alteration in level of expression or  sequence of genes. 
 
This could be explained by two mechanisms: 
 
 Mutation of G protein genes 
 
 Dysregulation in the process of posttranslational modification of  
 
          G protein 
 
                    
                   Diabetes mellitus being a disease with genetic predisposition ,there  
 
is a highincidence of post translational modification of protein leading to  
 
abnormal functioning or inappropriate localization of protein.
(86) 
 
 von Willibrand factor a glycoprotein constituent of the factor eight  
 
complex produces platelet activation. This vWF binds to platelet GpIb and IIb- 
 
IIIa receptor on the platelet membrane and promote clumping. Increase levels of  
 
vWF and increased activity has been documented in diabetics experimental 
 
studies.
(86)
 thus indicating the presence of endothelial damage. Similarly  
 insulin has shown to deplete the levels of von Willibrand factor in experimental  
 
 diabetic models.this mechanism also contributes the procoagulant state in  
 
 diabetes mellitus. 
 
 
 
INTRINSIC PLATELET ABNORMALITY 
 
                There are no clear studies which indicate whether the platelet  
 
dysfunction in diabetes is due to intrinsic platelet defect or as an impact of  
 
circulating factors on platelet function. 
(85)
.  
 
               The platelet sensitivity to ADP, epineohrine and thrombin is enhanced     
 
in human diabetics- which is independent of arachidonic acid and ADP  
 
pathways.This hyperaggregability was not reversible with insulin. 
 
 
                In the initial studies: increased thromboxane A2 (TXA2)  and  
 
prostaglandin E2 caused platelet  hyperaggregability which was reduced by  
 
inhibition of cyclooxygenase enzyme.it was later found that platelet aggregation  
 
did not correlate with thromboxane A2 synthesis , indicating it’s a multifactorial  
 
process. 
 
        
 Thus events occurring prior to eicosanoid production like IONOSITOL  
 
PHOSPHOLIPID turnover and CALCIUM release was focussed as a possible  
 
mechanism for platelet sensitivity. Elevated levels of calcium and suppressed  
 
intracellular magnesium was seen associated with platelet aggregation in  
 
diabetic.
(86)
The increase sensitivity of platelets to primary agonists like  
 
thrombin ,collagen ,ADP  is accompanied by increased phosphoinositide  
 
turnover. 
(87) 
 
  
 Similarly the basal and agonist(collagen) stimulated calcium levels where  
 
found to increase in platelets of diabetics than control subjects. 
 
 
 
ADVANCED GLYCOSYLATION ENDPRODUCTS 
 
                 Advanced glycosylation end products – produced by non - enzymatic  
 
 reaction between amino group of proteins and genes are found to be  
 
 accumulated in tissues of diabetics. 
            
 
               The glycosylation of  membrane proteins in platelets in turn reduce the  
 
 membrane fluidity in diabetic subjects..This effect on membrane fluidity  
 
results in platelet  hyperfunction. Likewise the glycosylation of subendothelial  
 
proteins  reduce the nitric oxide levels and in turn lead to  prothrombotic  
 
state. 
 
       
             The atherogenic dyslipedemia triad of DM  also affects the membrane  
 
fluidity. The LDL of diabetic persons had greater sensitivity and resulted in  
 
increased aggregation compared to control subjects and this significantly  
 
correlated to levels of glycosylation.
(88)
  
           
           
           The excess of free radicals production as a result of oxidative stress and  
 lipid peroxidation in diabetics result in decrease in prostacyclin and nitric oxide,  
 
thus amounting to platelet reactivity. 
 
 
 
ELEVATED GLYCOPROTEIN EXPRESSION 
      
                   Evidence points towars increased expression of glycoprotein Ib, IIb-
IIIa  on platelets of diabetics. Thusthese glycoprotein acts on the receptor for 
vWF ,  fibrinogen and other adhesion proteins involved in platelet aggregation- 
thus  platelet hyperreactivity. 
  
 
DIRECT EFFECTS OF INSULIN 
 
                Platelet contains a functional insulin receptor which is capable of  
 
binding insulin and autophosphorylation. Insulin reduces the platelet response to  
 
the primary agonists   , by downregulation of α2 receptors.Insulin also  
 
 maintains the sensitivity of platelets to PGI2. 
 
 
             Ud vardy et el
(88)
 demonstrated reduced number of insulin receptors  
 
and reduced affinity in diabetics.   
 
              Diabetes is a state associated with elevated platelet reactivity. Factors 
that contribute directly to greater platelet reactivity include metabolic 
abnormalities such as hyperglycemia andatherogenic hyperlipedemia, both 
insulin resistance (relative insulin deficiency) and absolute insulin 
deficiencyalong with  associated conditions such as oxidative stress, 
inflammation, and endothelial dysfunction.  The increased platelet aggregability 
and adhesiveness in diabetes are due to  the following: 
 
Reduced membrane fluidity 
 
Altered Ca+2 and Mg+2 homeostasis  
 
Increased arachiodonic acid metabolism 
 
Increased TXA2 synthesis 
 
Decreased prostacyclin and NO production 
 
Decreased antioxidant levels 
 
Increased expression of activation dependentadhesion molecules 
  
(e.g.  GPIIb/IIIa, p-selectin  ) 
 
 
 
                                   MEAN PLATELET VOLUME 
 
 
   
                MPV is an indicator of the average size and activity of platelets. 
Platelet size and volume depends on the circumstances of their production in the 
marrow. MPV is not related to aging of platelets in the circulation. Platelet 
parameters are very stable in most patients. 
 
                   Normal range of mean platelet volume in healthy individuals is  
8.9±1.2 fl. MPV is higher in type 2 diabetic patients than in non-diabetic  
patients in the range of  10.1±1.2 fl. 
 
 
 
                     Platelets when larger  are younger, increasingly aggregable and 
more  reactive. The larger platelets contain denser granules, secrete more β- 
 thromboglobulin, serotonin, and thromboxane A2 than their smaller  
counterparts. these changes produce a pro-coagulant state and cause  
thrombotic complications. This conceptualises a relationship between the  
platelet function mainly Mean platelet volume and vascular complications in  
DM .It implies that the changes in MPV reflect the state of  thrombogenesis .  
 Elevated MPV is an emerging marker for atherothrombosis  which plays 
 a pivotal role in the vascular complications of DM . 
  
 
 
  
  
 
 
 
        MATERIALS AND METHODS 
 
 
 
 
 
 
 
  
  
 
 
                     This study was performed at Government Royapettah Hospital 
from april 2014 to to September 2014. 
  
 
STUDY DESIGN AND PATIENT SELECTION 
                   This is a cross sectional , comparative study performed by selecting  
50 patients attending the diabetology OPD in Government Royapettah Hospital 
.Patients with type 2 diabetes ( confirmed by the ADA criteria ) for a more than 
a year and with good compliance to treatment for a minimum duration of 6 
months were selected by simple random sampling technique .  The study 
protocol was approved by the Ethical Committee for research in Government 
Kilpauk Medical College . 
 
INCLUSION CRITERIA: 
 Confirmed cases of type 2 diabetes on insulin therapy for minimum of 6 
months 
 Confirmed cases of type 2 diabetes on treatment with oral hypoglycaemic 
agents for a minimum of 6 months 
 
EXCLUSION CRITERIA 
 Patients with type 1 diabetes 
 Patients with abnormal platelet counts 
 Patients taking anti-platelet medications 
 Patients with chronic kidney disease 
 
 
After obtaining informed consent from the study subjects, a detailed history was 
elicited including history about the duration of diabetes and affected family 
members, treatment history .All the members were then subjected to a thorough 
clinical examination by obtaining , height, weight, systemic examination along 
with the examination of fundus. The following tests were performed on the 
study  subjects . 
 
Fasting blood glucose 
Postprandial blood glucose 
HbA1C 
Blood urea 
Serum creatinine 
Urine for albumin and sugar 
Complete blood count ( including platelet count ) 
Mean platelet volume 
The fasting and postprandial blood glucose measurements were made following 
a standardized test meal. 
 
 
STANDARDIZED MEAL TEST 
A standardized mixed meal was given to all the patients after an overnight fast. 
The meal consisted of three idlis and a standard serving of sambar and a 
standard serving of coconut chutney. The total energy content of the standard 
meal was 9 Kcal/kg, with 60% of the total energy from carbohydrates, 20% of 
the energy from fat and 20 % of the energy from proteins. Blood glucose levels 
were then measured. 
 
Complete hemogram and mean platelet volume was performed by cellenium 19  
 
cell counter method. 
 
Data analysis was performed by SPSS using Student's t test and Pearson  
 
Correlation 
 
 
 
 
 
 
 
 
 
 
 
  
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        OBSERVATION AND RESULTS  
 
 
  
  
The study population of 50 analysed and the results were tabulated as follows.  
 
 
 
 
 
 
THE DISTRIBUTION OF STUDY POPULATION ACCORDING TO AGE  
 
AND CORRELATION WITH MPV 
 
 
 
  
 
         Age ( yrs) N Mean Std. Deviation 
 
 
 
 
 
P value 
      
        <= 40 2 10.800 .0000 
 
        
        41-55 28 10.886 .5038 
.715 
        
        > 55 20 10.770 .4692 
 
 
   
 
 
 
 In the study population of 50 the mean age was 52.56 years. 
 
 20 subjects where above 55 yrs of age and had a mean MPV of 10.770 fl  
 28 of them where in the age group of 41- 55 years and the mean MPV of 
this age group was 10.886 fl and standard deviation of ± 0.5038. 
 And 2 subjects where below 40 years of age   and the mean MPV in this 
age group was 10.80 fl. 
 
 
  
 
There was no statistically significant association between age and mean 
platelet volume in the study. ( p value = 0.715) 
 
Table 1  MPV with age wise distribution of study population 
 
 
 
 
  
DISTRIBUTION OF MPV ACCORDING TO AGE 
      <= 40        41-55        > 55
 THE DISRTIBUTION OF STUDY POPULATION ACCORDING TO BMI  
 
AND   ITS CORRELATION WITH MPV 
 
 
 
              BMI (Asian population) 
N 
  
Mean 
  
Std. Deviation 
  
 
 
 
 
P value 
 
 
         Normal (<22.99 ) 5 10.880 .3701 
 
 
         Over weight(23 – 27.99 ) 36 10.792 .4795 
 
 
         Obese ( > 28 ) 9 10.989 .5372 
.539 
 
   
 
 
 
 
 
 In the study population  5 were classified as having normal BMI ( for 
the Asian population ) and the mean MPV of this group was 10.880 
±0.37 fl. 
 36 people in the study population were found to be overweight . the 
mean MPVvalue of this group was 10.792 ±0.4795 fl. 
  9 of the study subjects were classified under the obese group and their 
mean MPV was 10.989 ±0.5372 fl. 
 
 There was no significant statistical correlation between the mean platelet 
volume values and BMI.( p value = 0.539 ).  
 
 
Table 2 MPV and distribution of study population according to BMI 
 
 
 
 
 
 
DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
DURATION OF DIABETES AND ITS CORRELATION WITH MPV 
 
 
 
 
 
Duration of     
 
     DM(yrs) 
 
Number 
  
Mean MPV 
  
Std. Deviation 
  P value 
    < 3 
20 10.675 .4655 
 
            .180 
   3-5 
11 10.845 .3857  
   5-10 
13 11.046 .5238  
   > 10 
6 10.900 .4858  
 
    
 
 
 
 In the study population 20 people are found to have DM for less than 3 
years and the mean MPV of this group is 10.675 ±0.4655 fl. 
 
 
 And 11 persons  come under the 3-5 year group and the mean MPV of 
them is 10.845 ±0.3857 fl. 
 
 
 
 
 
 
 
Figure 13  distribution of study population basd on  Duration of diabetes 
  
 
 
 
 13 persons fall under the group with DM for 5- 10   years and the mean 
MPV in this category is 11.046 ±0.5238 fl. 
 
 6  out of the 50 in the study population had diabetes for more than 10 
years and the mean MPV of this group was  10.9 ± 0.4858 fl. 
 
 
There was no statistical correlation   between Mean Platelet Volume  and the 
duration of diabetes mellitus.( p value = 0.180 ) 
 
 
 
 
 
 
 
 
 
 
DISTRIBUTION OF STUDY POPULATION ACCORDING TO FASTING  
 
BLOOD GLUCOSE AND ITS CORRELATION  WITH  MPV. 
 
 
 
 
 
 
 
   Fasting blood           
       glucose  
N 
  
Mean MPV 
  
Std. Deviation 
  
 
 
 
 P value  
    
   < 100 
 
10 
 
10.400 
 
.3367 
 
    
   100-126 
 
19 
 
10.784 
 
.4902 
.ooo ** 
    
   > 126 
 
21 
 
11.090 
 
.3562 
 
     
 
If the P value is  0.000 to  0.010 then denoted by ** it imply Significant at 1 level (Highly Significant ) 
 
 
  
 
 
 
 
 
 
 10 among the 50 in the study population had a Fasting Blood Glucose 
<100 mg/dl. And the mean MPV of this group was 10.4 ± 0.3367 fl. 
 
 19 of them had a Fasting Blood Glucose in the range of 100-126 mg/dl 
and the mean MPV was 10.784 ± 0.4902 fl. 
 
 21 persons in the study population had a Fasting Blood Glucose >126           
mg /dl and the mean MPV was 11.09 ± 0.3562 fl. 
 
 
 
 
 
 
 
The Fasting Blood Glucose values showed a positive correlation with MPV 
which was statistically significant. (p value =0.000 ). 
 
 
 
 
DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO  
 
POSTPRANDIAL BLOOD GLUCOSE AND ITS CORRELATION WITH  
 
MPV. 
 
 
 
 
 Among the 50 members included in the study only 1 had a post prandial 
blood glucose <140 mg /dl  and the MPV was 9.9 fl. 
 25 members had  postprandial blood glucose ranging from 140-200 mg/dl 
and the mean MPV of this group was 10.668 ±0.4811 fl. 
10.4 
10.784 
11.09 
10
10.2
10.4
10.6
10.8
11
11.2
   < 100    100-126    > 126
MPV  and  Fasting blood glucose    
 The remaining 24 persons had postprandial blood glucose values >200 
mg /dl and the mean MPV of this group was 11.05 ±3587 fl. 
 
 
 
 
 
Figure 14 distribution of study population  according to PPBG 
 
 
 
 
  
Postprandial blood 
glucose(mg/dl)         NUMBER 
Mean MPV 
  
Std. Deviation 
  P value 
 
        < 140 
 
1 
 
9.900 
. 
 
   .002* 
 
       140-200 
 
25 
 
10.668 
 
.4811 
 
 
        > 200 
 
24 
 
11.050 
 
.3587 
 
     
  If the P value is 0.011 to 0.050 then denoted by * it imply Significant at 5 level (Significant ) 
 
 
 
 
 Analysis of data revealed a positive correlation between postprandial  
 
blood glucose and mean platelet volume with a p value =0.002. 
 
 
 
 
Figure 15MPV and postprandial blood glucose 
 
 
 
DISTRIBUTION OF STUDY POPULATION ACCORDING TO HbA1C 
LEVELS AND ITS CORRELATION WITH MPV 
 
 
 
 The mean HbA1C values of the study population was 7.762 . 
 
  
 
 22 members of the study had HbA1C <7 and the mean MPV of this group 
was 10.518 ± 0.3431 fl. 
 17 were categorised under the group with HbA1C 7 - 8.9 and men MPV 
of this class was 10.947 fl with a standard deviation of 0.4346 .  
 
 
 4 members had HbA1C values between 9 and 10 ,with the mean MPV of 
this group being 11.25 ±0.4123 fl. 
 And 7 subjects had HbA1C >10 .the mean MPV of this group was 
11.329fl  with a standard deviation of 0.2498. 
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     HbA1C 
  
N 
  
Mean MPV 
  
Std. Deviation 
  
 
 
P value 
 
          < 7 
 
22 
 
10.518 
 
.3431 
 
 
         7-8.9 
 
17 
 
10.947 
 
.4346 
 
.000** 
 
         9-10 
 
4 
 
11.250 
 
.4123 
 
 
         > 10 
 
7 
 
11.329 
 
.2498 
 
     
  If the P value is  0.000 to  0.010 then denoted by ** it imply Significant at 1 level (Highly Significant ) 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 distribution of study population  according to HbA1C 
 
 
 
 
Data analysis demonstrated a positive correlation between HbA1C and  
 mean platelet volume. ( p value = 0.000) 
 
 
 
 
 
 
 
CORRELATION BETWEEN BETWEEN BLOOD UREA VALUES AND 
MEAN PLATELET VOLUME  
 
 
 
 
Blood Urea N MPV Std. Deviation P value 
Normal    (<40 mg/dl) 
45 10.818 .4638 
.424  
Abnormal( >40 mg/dl) 
5 11.000 .6285 
 
 
 
 
 
 
 
Among the 50 subjects under study, blood urea was found to be elevated in 5 
individuals and  the  average mean platelet volume of them was 11.0 fl with a 
standard deviation of ± 0.6285. And the urea values were normal ( < 40mg/dl ) 
in the remaining 45 subjects with mean platelet volume being  10.818 fl  with a 
standard deviation of ±0.4638. 
 
 
 
Figure 17 distribution of study population according to blood urea levels 
 
                                
 
Although the MPV in subjects with an abnormal blood urea levels were higher 
there was no statistical significance associated with it. 
 
 
CORRELATION BETWEEN SERUM CREATININE AND MEAN 
PLATELET VOLUME 
 
 
 
 
 
 
Sr.Creatinine 
N Mean Std. Deviation  P value 
Normal ( < 1.0 
mg/dl ) 32 10.753 .4725 
0.103 
Abnormal ( .1.0 
mg/dl) 18 10.983 .4643 
 
  
In the study population 32 people had serum creatinine values within the normal 
range ( < 1.0 mg/dl ) and the  average mean platelet volume of these subjects 
was 10.753fl  with a standard deviation of ± 0.4725 . 
And  the remaining 18 people had an elevated serum creatinine levels ( >1.0 
mg/dl ) and their average mean platelet volume was 10.983 fl with a standard 
deviation of ± 0.4643. 
 
 
 
 
 
The correlation between MPV and serum creatinine levels was not statistically 
significant . ( p value = 0.103 ) 
 
 
DISTRIBUTION AND CORRELATION OF PROTEINURIA AND MEAN 
PLATELET VOLUMES. 
 
Among the study population of 18 members were found to have proteinuria . 
 
 
                                                            
                                    
proteinuria N Mean MPV Std. Deviation P value  
  
  Absent  32 10.647 .3959 .ooo** 
    
 present 18 11.172 .4309  
  If the P value is  0.000 to  0.010 then denoted by ** it imply Significant at 1 level (Highly Significant ) 
 
 
 
 
 
  
 the mean MPV in the group with proteinuria was found to be  11.172fl 
with a standard deviation of  0.4309 . 
 in the group were there was no proteinuria the mean MPV was 10.647 
±3959 fl. 
 
  
There was a positive correlation between MPV and proteinuria , MPV was 
significantly high in the group with proteinuria. ( p value = 0.000) 
  
 
 
CORRELATION BETWEEN RETINOPATHY AND MEAN PLATELET 
VOLUME  
 
 Among the 50 subjects 12 of them were found to have various stages of 
diabetic  retinopathy. 
 
 And the mean platelet volume values of the group with retinopathy was 
higher than that without retinopathy. 
N Mean MPV
32 
10.647 
18 
11.172 
PROTEINURIA AND MPV 
   
 
 In the 12 persons with retinopathy the mean MPV was found to be 11.208 
fl with standard deviation of 0.3315 . 
 And the mean MPV in the non  retinopathy group was 10.718 ± 0.4591 fl. 
 
 
There was a positive correlation between mean platelet volume and 
diabetic retinopathy which was statistically significant. ( p value = 0.001 ) 
 
 
 
 
 
retinopathy 
N Mean MPV Std. Deviation 
 
P value 
     absent 
38 10.718 .4591 
 
.001 
76% 
24% 
RETINOPATHY IN STUDY GROUP 
retinopathy
     absent
present
present 
12 11.208 .3315 
 
  If the P value is  0.000 to  0.010 then denoted by ** it imply Significant at 1 level (Highly Significant ) 
 
 
 
 
 
 
 
Table 3 MPV  and retnopathy correlation 
 
 
COMPARISON OF MEAN PLATELET VOLUME IN TYPE 2 DIABETICS 
TAKING INSULIN AND ORAL HYPOGLCAEMIC AGENTS. 
 
 In the study population of 50 , 19 members were found being treated with 
insulin and the remaining 31 of them were on oral hypoglycaemic agents. 
 
 
               
Figure 18 distribution of study population  based on therapy 
 
 
 The group with insulin was found to have a mean  MPV ehich was much 
lower than the OHA group. 
 The mean MPV of the insulin group was 10.505 fl with astandard 
deviation of 0.3535 . 
 The mean MPV in the group taking oral hypoglcaemic agents was found 
to be 11.039 fl with a standard deviation of 0.4318. 
 
Treatment 
modality N Mean MPV Std. Deviation P value 
Insulin 
19 10.505 .3535 
<0.001** 
OHA 
31 11.039 .4318 
  If the P value is  0.000 to  0.010 then denoted by ** it imply Significant at 1 level (Highly Significant ) 
 
Insulin 
OHA 
Insulin OHA
 There was a definite correlation between MPV and both the groups. The 
MPV of the subjects on insulin therapy was lower than the OHA group. 
And this difference in mean platelet volume between the 2 groups was 
found to be statistically significant . ( p value <0.001  
 
 
 
 
 
 
 
                            Thus at the end of the study age, duration of diabetes mellitus , 
body mass index, blood urea levels, serum creatinine values did not have any 
statistically significant correlation with mean platelet volume. 
 
 
 
                           And the levels of fasting blood glucose, postprandial blood 
glucose , HbA1C, proteinuria and retinopathy was found to have a positive 
correlation with mean platelet volume. 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
                                   DISCUSSION 
 
  
                         The mean MPV value of the study population of 50 diabetic 
individuals was  10.836 fl and this is higher than that of the normal healthy 
population. This is in accordance to the study published by Kodiatte et al,, 
Hekimsoy et al., Demirtunc et al., Zuberi et al., Atea et al., Jindal et al., and 
Papanas et al. where the mean MPV was 8.27 ±0.74 fl. The study included 24 
females and 26 males and the mean age of the study population was 52.56 years 
, and the study by Pradeep et al had a mean age of 56.9 years.and the mean 
duration of diabetes among the study population was found to be 11.15 years 
and the study by Kodiatte et al  had a mean duration of diabete at 6.2 years. 
                     A study by Shah B et al  demonstrated a significant association 
between mean platelet volume and the presence and severity of diabetes.and this 
association was more evident in the group with poor glycaemic control. 
          
                The body mass index ( fir the Asian population ) on this study did not 
have any corre;ation with MPV ,this again is in accordance to the study by 
Coban et al who shoed that there was no correlation between the two. The mean 
BMI of the study population was 25.97 kg/m2. 
 
               The mean fasting blood glucose values of the study population was 
131.42 ± 45.4 mg/dl. In the study by Kodiatte et al the mean fasting blood 
glucose value was 151.5 ± 71.7 mg/dl. There was positive correlation between 
the fasting blood sugar values and mean plaetelet volume.this outcome is 
reiterated by the study results of Kodiatte et al also having similar outcome. 
 
                The postprandial blood glucose values in the study by Kodiatte et al 
had a mean of 252.9 ±94.85 mg/dl. While in our study group the mean PPBS 
values were 219.72 ±74.6 mg/dl.and there was a positive correlation between 
PPBS values and mean platelet volume similar to that in the former. 
 
               The HbA1C values in our study population was 7.762 ± 1.83 
While that of the study by Kodiatte et al was 9.13 ±2.53 . our study revealed a 
positive correlation between HbA1C levels and mean platelet volume, this is in 
accordance to the former publication of Kodiatte et al. 
 
            The mean platelet volume values of subjects in the study population was 
not found to correlate with the blood urea and serum creatinine values. 
 
               The values of mean platelet volume was higher in diabetics with 
proteinuria than in those who lacked it.And there was a significant positive 
correlation between proteinuria and MPV .thus indicating a correlation existing 
between MPV and diabetic nephropathy.   
 
      
                  Likewise the MPV values were higher in subjects with diabetic 
retinopathy and there was a definite positive correlation between the two. 
 
 
                    In our study the MPV was significantly high in patients on oral 
hypoglycaemic agents rather than those on insulin therapy. The mean MPV of 
the group with insulin therapy was 10.505 ±0.3535fl and the mean MPV in the 
OHA group was 11.039 ± 0.4318 fl. This derivation was statistically significant 
( p value = 0.000), and it is in accordance to the outcome of the study by 
Pradeep.V et al. This indicates that a strict glycaemic control with early 
initiation of insulin can reduce platelet hyperactivity. 
 
                  
                  In our study the MPV levels were higher in subjects with 
microvascular complications , and is supported by other studies like  Ates et 
al. 
[12]
 and Papanas et al and Kodiatte et al.This indicates that diabetes mellitus 
has a significant influence on the platelet function and microvascular 
complications have a definite association with platelet hyperactivity. 
 
 
               
 
  
LIMITATIONS OF THE STUDY 
 
                             This study has considered a population of 50 and thus the 
appropriate representation of the population and better outcomes could be 
attained by increasing the sample size. The restriction of study to small 
geographical area is also a constraint.  
               
                                  
 
 
 
 
 
 
 
 
 
 
 
 
  
       CONCLUSION  
 
 Mean platelet volume values were significantly lower in diabetic people 
on insulin therapy than those on oral hypoglycaemic agents. 
 
 There was a positive correlation between mean platelet volume and 
microvascular complication indicating  a higher platelet activity in this 
subgroup. 
 
 Emphasis should be laid on a  strict  glycemic control and early initiation 
of insulin therapy in order to prevent the vascular complications 
associated with diabetes.  
 
 Mean platelet volume can serve as a cost effective marker of 
atherothrombosis  and  helps monitor platelet activity.  
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Sheet1
name age ht wt  BMI 
durati
on of 
DM familt histtrea mentFBS PPBS HbA1C Bld.ureasr.creatinineu. albuminu.sugarfundus neuropathyplatelet countMPV
sudhakar 46 1.72 65 ##### 5 Y OHA 142 210 7.8 32 0.8 nil nil normal nil 2.89 10.6
muneswari 67 1.54 67 ##### 14 N OHA 270 347 11.5 40 1.1 2# 1# mod npdr P 2.67 11.5
kasthuri 60 1.56 58 ##### 7 N OHA 111 170 7.2 28 0.9 nil nil normal nil 3.12 11
syed mustaq ahmed53 1.62 74 ##### 10 Y insulin 116 178 6.9 24.2 1.3 2# nil pdr,photocoagulation doneP 3.25 11.2
vijaya 46 1.58 68 ##### 7 Y OHA 276 318 11.6 29.6 1.1 nil nil normal nil 2.89 11.5
sekar 60 1.74 78 ##### 1 N OHA 87 130 6.5 18.8 0.8 nil nil normal nil 3.3 9.9
kantha 65 1.62 70 ##### 15 N OHA 145 278 8.4 34.2 1.6 2# nil mod npdr P 3.67 11.2
kadumbadi 62 1.5 80 ##### 4 N OHA 118 182 7.6 30 1.1 nil nil normal nil 2.67 10.6
thahira begum62 1.45 62 ##### 20 Y insulin 95 194 6.4 38.3 1.8 3# 2# severe npdrP 2.41 10.7
seeni ibrahim 44 1.75 76 ##### 1.5 N OHA 151 301 10.6 28.4 1 nil nil normal nil 2.78 10.9
akthar basha 44 1.6 57 ##### 11 N OHA 110 247 7.4 26 1 micro albuminurianil norm l nil 3.1 11.1
janarthanan 66 1.72 72 ##### 5 Y insulin 105 177 6.8 35 0.9 nil nil normal P 3.65 10.4
kathirunisha 29 1.5 49 ##### 4 Y OHA 108 301 9.2 24.8 0.8 nil nil normal nil 2.45 10.8
selvam 41 1.56 59 ##### 3 Y insulin 100 184 6.6 16.9 0.9 nil nil normal nil 3.09 9.9
muthukumar 58 1.64 70 ##### 10 N insulin 96 159 5.9 36 1 nil nil normal nil 2.85 10.2
 sheila sharon 46 1.58 68 ##### 5 Y OHA 142 199 7.1 29 1 nil nil normal nil 3.9 11
renganathan 72 1.7 72 ##### 14 N insulin 111 169 6.8 36 1.1 microalbuminurianil normal nil 2.49 10.8
mariappan 46 1.68 74 ##### 3 N OHA 98 154 6.5 26 0.9 nil nil normal nil 2.98 10.7
robert 42 1.74 76 ##### 2 Y insulin 125 186 7.4 35 1.1 nil nil normal nil 3.15 10.2
jency 56 1.55 64 ##### 7 N OHA 174 258 9 41 1.2 1# nil mild npdr P 2.94 11.6
kavitha 52 1.5 63 ##### 6 N OHA 102 178 7.8 38 1 microalbuminurianil normal nil 3.45 12.1
usman 64 1.6 60 ##### 9 N insulin 94 176 6.5 38.4 0.9 nil nil normal nil 2.78 10.6
angaiyakani 61 1.52 62 ##### 6 N insulin 122 211 7 26 0.87 nil nil normal nil 2.83 10.5
dinesh 45 1.68 65 ##### 1 Y OHA 104 220 7.1 18.9 0.97 nil nil normal nil 2.67 10.9
selvakumar 54 1.64 64 ##### 2 Y OHA 88 165 6.6 26.8 1 nil nil normal nil 3.18 10.7
sampath 50 1.75 76 ##### 3 N insulin 114 192 6.5 26 1 nil nil normal nil 2.89 9.8
harini 47 1.52 62 ##### 2 N OHA 143 304 10.3 31.6 0.88 2# nil mod npdr P 3.26 11.6
uma maheshwari43 1.5 68 ##### 2 Y insulin 111 195 7.1 33 1.1 nil nil normal nil 2.52 10.4
siddarth 39 1.64 73 ##### 1 Y OHA 112 195 7 29.2 0.9 nil nil normal nil 2.99 10.8
menaka 53 1.64 68 ##### 5 N OHA 143 277 8.6 38 1.2 1# nil normal nil 2.79 11.1
nirmala 44 1.56 74 ##### 3 Y insulin 204 357 9.1 40 1 microalbuminurianil normal nil 3.22 11
amaiappan 68 1.66 70 ##### 12 N insulin 99 174 6.2 42 1.2 1# nil normal P 2.9 10.1
kaniappan 61 1.56 61 ##### 10 N OHA 242 287 10.7 52 1.5 3# 1# mild npdr P 3.35 11.4
kanmani 57 1.52 63 ##### 5 N insulin 132 224 6.8 26.4 0.89 nil nil normal nil 2.64 10.7
muthumeera 48 1.6 66 ##### 3 N OHA 127 211 6.9 33 0.85 nil nil normal nil 2.73 10.7
sulaiman 53 1.73 83 ##### 8 Y OHA 137 253 7.9 36 1.3 1# nil mod npdr P 2.87 11.2
arumugam 55 1.66 80 ##### 6 Y insulin 130 201 6.9 40.3 1.1 nil nil mild npdr P 2.56 10.6
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aathilakshmi 57 1.54 73 ##### 9 Y insulin 120 185 6.6 33 0.9 nil nil normal nil 2.76 10.8
ranjith 46 1.6 65 ##### 3 Y OHA 95 155 6.5 25.7 1 nil nil normal nil 2.68 10.6
latha 49 1.54 59 ##### 3 N OHA 112 198 7.5 30.4 0.96 nil nil normal nil 3.07 11
subramanian 64 1.58 63 ##### 5 N insulin 103 178 6.5 22.9 0.89 nil nil normal nil 3.12 10.5
bazeera 44 1.48 57 ##### 3 N OHA 130 214 7.2 34 1 1# nil normal nil 2.68 10.9
jothi 45 1.55 58 ##### 2 N insulin 107 195 6.7 38 1 nil nil normal nil 3.33 10.6
kannan 56 1.64 65 ##### 7 N OHA 133 256 7.4 26.7 1.1 1# nil mild npdr P 3.45 10.9
shanmugam 60 1.6 61 ##### 5 N insulin 97 188 6.8 36 0.83 nil nil normal nil 2.67 10.6
bhavani 55 1.6 57 ##### 2 Y OHA 153 218 7.4 27 1 nil nil normal nil 2.82 10.5
neelakandan 46 1.68 74 ##### 3 Y OHA 241 375 11.6 40.6 2.1 3# 1# severe npdrP 2.56 11.3
chithra 44 1.48 58 ##### 1 N OHA 143 235 10.5 33.6 1 nil nil mild npdr nil 2.92 11.1
sudha 47 1.52 60 ##### 4 N OHA 135 244 9.6 38.5 0.99 nil nil normal nil 2.64 11.6
manikandan 56 1.7 65 ##### 5 Y OHA 118 183 7.6 37.9 1.2 2# nil mod npdr P 2.93 11.4
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ABBREVIATIONS 
 
MPV= MEAN PLATELET VOLUME 
BMI= BODY MASS INDEX 
FFA= FREE FATTY ACID 
HDL= HIGH DENSITY LIPOPROTEIN 
LDL= LOW DENSITY LIPOPROTEIN 
DM= DIABETES MELLITUS 
HLA= HUAMN LEUKOCYTE ANTIGEN 
IR= INSULIN RESISTANCE 
OGTT= ORAL GLUCOSE TOLERANCE TEST 
GLUT= GLUCOSE TRANSPORTER 
IRS= INSULIN RECEPTOR SUBSTRATE 
CAD= CORONARY ARTERY DISEASE 
CPT= CARNITINE PALMITOYL TRANSFERASE 
PPAR= PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR 
TNF= TUMOUR NECROSIS FACTOR 
PKC= PHOSPHOKINASE C 
TGF= TRANSFORMING GROWTH FACTOR 
CRP= C REACTIVE PROTEIN 
IL= INTERLEUKIN 
VLDL= VERY LOW DENSITY LIPOPROTEIN 
TIA= TRNASIENT ISCHAEMIC ATTACK 
TLR= TOLL LIKE RECEPTOR 
NCP= NON COLLAGEN PROTEIN 
CAM= CELL ADHESION MOLECULES 
 
 
                                                       PROFORMA 
   NAME :                                                                       OCCUPATION: 
  AGE/SEX:                                                                   ADDRESS: 
Duration of DM: 
Treatment hist and duration: 
Compliance: 
Hist relating to complications of DM: 
Past hist and drug intake: 
Personal hist: 
 
PHYSICAL EXAMINATION: 
Height                                                                  Weight 
 BMI: 
Vitals : 
CVS : 
RS : 
Neurological examination: 
Fundus examination: 
 
INVESTIGATIONS: 
1.FBG 
2. 2 hr PPBG 
3.HbA 1C 
4. CBC 
5. MPV 
6.LIPID PROFILE 
7. BLOOD UREA 
8.SERUM CREATININE 
9.URINE ALBUMIN 
10.URINE SUGAR 
11. ECG 
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